var title_f35_52_36672="Normal and abnormal voiding";
var content_f35_52_36672=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F79681&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F79681&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 555px\">",
"   <div class=\"ttl\">",
"    Normal and abnormal voiding",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 535px; height: 303px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_52_36672=[""].join("\n");
var outline_f35_52_36672=null;
var title_f35_52_36673="Eruptive syringoma - shoulder";
var content_f35_52_36673=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F79695&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F79695&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Eruptive syringoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple flesh-colored and hyperpigmented small papules are present on the shoulder and chest.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_52_36673=[""].join("\n");
var outline_f35_52_36673=null;
var title_f35_52_36674="Adrenal neuroblastoma";
var content_f35_52_36674=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F78302&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F78302&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Neuroblastoma arising from the adrenal gland",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 504px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The tumor is heterogeneous in appearance and contains calcifications. Note how it surrounds and displaces the aorta.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Heidi V Russell, MD, Jason M Shohet, MD, and Jed G Nuchtern, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_52_36674=[""].join("\n");
var outline_f35_52_36674=null;
var title_f35_52_36675="Camphor and phenol: Patient drug information";
var content_f35_52_36675=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Camphor and phenol: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/50/24354?source=see_link\">",
"     see \"Camphor and phenol: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F144891\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Campho-Phenique&reg; [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10012779\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691619",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to ease the pain caused by sunburn, skin irritation, and cold sores.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10012778\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701694",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to camphor, phenol, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10012783\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697759",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use care when a large part of the skin is involved or where there are open wounds.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696817",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use coverings (bandages, dressings, make-up) unless told to do so by your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10012784\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698344",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Skin irritation.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10012786\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699049",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10012781\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694772",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take this drug by mouth. Use on your skin only. Keep out of your mouth, nose, and eyes (may burn).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696250",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash your hands before and after use. Do not wash your hands after use if putting this on your hand.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694623",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Clean affected part before use. Make sure to dry well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694440",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put a thin layer on the affected skin and rub in gently.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10012782\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696441",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put on a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696452",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not put on 2 doses or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696549",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Many times this drug is used on an as needed basis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10012787\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699262",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from heat.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10012788\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11450 Version 31.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-41.196.66.12-562CF1C545-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_52_36675=[""].join("\n");
var outline_f35_52_36675=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144891\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012779\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012778\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012783\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012784\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012786\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012781\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012782\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012787\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012788\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?23/50/24354?source=related_link\">",
"      Camphor and phenol: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_52_36676="Magnesium gluconate: Pediatric drug information";
var content_f35_52_36676=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Magnesium gluconate: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?34/10/34980?source=see_link\">",
"    see \"Magnesium gluconate: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?40/36/41540?source=see_link\">",
"    see \"Magnesium gluconate: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F190866\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Magonate&reg; [OTC];",
"     </li>",
"     <li>",
"      Magtrate&reg; [OTC];",
"     </li>",
"     <li>",
"      Mag&reg;-G [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1023004\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Electrolyte Supplement, Oral",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Magnesium Salt",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F13291901\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Recommended daily allowance of magnesium: Oral: 40 mg/day",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1023018\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?34/10/34980?source=see_link\">",
"      see \"Magnesium gluconate: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral:",
"     <b>",
"      Note:",
"     </b>",
"     Achieving optimal magnesium levels using oral therapy may be difficult due to the propensity for magnesium to cause diarrhea: I.V. replacement may be more appropriate particularly in situations of severe deficit.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Recommended daily allowance of magnesium: See table.",
"    </p>",
"    <table border=\"1\" frame=\"border\" rules=\"all\">",
"     <caption style=\"text-align:center;\">",
"      Magnesium &minus; Recommended Daily Allowance (RDA) and Estimated Average Requirement (EAR) (in terms of elemental magnesium)",
"     </caption>",
"     <col align=\"left\" width=\"150\">",
"     </col>",
"     <col align=\"center\" width=\"150\">",
"     </col>",
"     <col align=\"center\" width=\"150\">",
"     </col>",
"     <thead valign=\"middle\">",
"      <tr>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Age",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         RDA",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         (mg/day)",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         EAR",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         (mg/day)",
"        </p>",
"       </th>",
"      </tr>",
"     </thead>",
"     <tbody valign=\"middle\">",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         1 to &lt;6 mo",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         40",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         30",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         6 to &lt;12 mo",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         60",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         75",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         1-3 y",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         80",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         65",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         4-8 y",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         130",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         110",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" colspan=\"3\">",
"        <p style=\"text-indent:0em;\">",
"         <b>",
"          Male",
"         </b>",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;margin-left:2em;\">",
"         9-13 y",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         240",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         200",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;margin-left:2em;\">",
"         14-18 y",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         410",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         340",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" colspan=\"3\">",
"        <p style=\"text-indent:0em;\">",
"         <b>",
"          Female",
"         </b>",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;margin-left:2em;\">",
"         9-13 y",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         240",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         200",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;margin-left:2em;\">",
"         14-18 y",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         360",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         300",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     Prevention and treatment of hypomagnesemia:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children: 10-20 mg/kg",
"     <b>",
"      elemental",
"     </b>",
"     magnesium per dose up to 4 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Adults: 500-1000 mg 3 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Dosing adjustment in renal impairment:",
"     </b>",
"     Patients in severe renal failure should not receive magnesium due to toxicity from accumulation. Patients with a Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;25 mL/minute receiving magnesium should have serum magnesium levels monitored.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F190857\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Liquid, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Magonate&reg;: 1000 mg/5 mL (355 mL) [contains sodium benzoate; melon flavor; equivalent to elemental magnesium 54 mg /5 mL]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 500 mg [equivalent to elemental magnesium 27 mg], 550 mg [equivalent to elemental magnesium 30 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Magonate&reg;: 500 mg [scored; equivalent to elemental magnesium 27 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Magtrate&reg;: 500 mg [equivalent to elemental magnesium 27 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mag&reg;-G: 500 mg [equivalent to elemental magnesium 27 mg]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F190848\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Tablet",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F3416700\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:0em;\">",
"     Solution: Mix with water and administer on an empty stomach.",
"    </p>",
"    <p style=\"text-indent:0em;\">",
"     Tablet: Take with full glass of water.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1023005\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment and prevention of hypomagnesemia; dietary supplement",
"    </p>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F190887\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Gastrointestinal: Diarrhea (excessive oral doses)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1023006\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to magnesium salt(s) or any component; serious renal impairment, myocardial damage, heart block; patients with colostomy or ileostomy, intestinal obstruction, impaction, or perforation, appendicitis, abdominal pain",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F3416698\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with impaired renal function (accumulation of magnesium may lead to magnesium intoxication)",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F3416697\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Multiple salt forms of magnesium exist; close attention must be paid to the salt form when ordering and administering magnesium;",
"     <b>",
"      incorrect selection or substitution of one salt for another without proper dosage adjustment may result in serious over- or under-dosing",
"     </b>",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Magonate&reg; solution contains sodium benzoate; benzoic acid (benzoate) is a metabolite of benzyl alcohol; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates;",
"     <i>",
"      in vitro",
"     </i>",
"     and animal studies have shown that benzoate displaces bilirubin from protein binding sites; avoid use of Magonate&reg; solution in neonates",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299633\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F190855\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alfacalcidol: May increase the serum concentration of Magnesium Salts.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bisphosphonate Derivatives: Magnesium Salts may decrease the serum concentration of Bisphosphonate Derivatives.  Management: Avoid administration of oral magnesium salts within: 2 hours before or after tiludronate/clodronate/etidronate; 60 minutes after oral ibandronate; or 30 minutes after alendronate/risedronate.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Pamidronate; Zoledronic Acid.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcitriol: May increase the serum concentration of Magnesium Salts.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers: May enhance the adverse/toxic effect of Magnesium Salts. Magnesium Salts may enhance the hypotensive effect of Calcium Channel Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferiprone: Magnesium Salts may decrease the serum concentration of Deferiprone.  Management: Separate administration of deferiprone and oral medications or supplements that contain polyvalent cations by at least 4 hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eltrombopag: Magnesium Salts may decrease the serum concentration of Eltrombopag.  Management: Separate administration of eltrombopag and any polyvalent cation (e.g., magnesium-containing products) by at least 4 hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mycophenolate: Magnesium Salts may decrease the serum concentration of Mycophenolate.  Management: Separate doses of mycophenolate and oral magnesium salts. Monitor for reduced effects of mycophenolate if taken concomitant with oral magnesium salts.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Neuromuscular-Blocking Agents: Magnesium Salts may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphate Supplements: Magnesium Salts may decrease the serum concentration of Phosphate Supplements.  Management: Administer oral phosphate supplements at least 1 hour before, or 2 hours after, oral magnesium salt administration.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Potassium Phosphate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinolone Antibiotics: Magnesium Salts may decrease the absorption of Quinolone Antibiotics. Of concern only with oral administration of both agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tetracycline Derivatives: Magnesium Salts may decrease the absorption of Tetracycline Derivatives. Only applicable to oral preparations of each agent.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trientine: Magnesium Salts may decrease the serum concentration of Trientine. Trientine may decrease the serum concentration of Magnesium Salts.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F3012936\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Magnesium crosses the placenta; serum concentrations in the fetus are similar to those in the mother (Idama, 1998; Osada, 2002).",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1023014\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Magnesium is important as a cofactor in many enzymatic reactions in the body. There are at least 300 enzymes which are dependent upon magnesium for normal functioning. Actions on lipoprotein lipase have been found to be important in reducing serum cholesterol. Magnesium is necessary for the maintaining of serum potassium and calcium levels due to its effect on the renal tubule. In the heart, magnesium acts as a calcium channel blocker. It also activates sodium potassium ATPase in the cell membrane to promote resting polarization and produce arrhythmias.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1023016\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral: Up to 30%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Renal with unabsorbed drug excreted in feces",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F3426358\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Magnesium gluconate 500 mg = 27 mg",
"     <b>",
"      elemental",
"     </b>",
"     magnesium = 2.4 mEq magnesium",
"    </p>",
"    <table border=\"1\" frame=\"border\" rules=\"all\">",
"     <caption style=\"text-align:center;\">",
"      Elemental Magnesium Content of Magnesium Salts",
"     </caption>",
"     <col align=\"left\" width=\"190\">",
"     </col>",
"     <col align=\"center\" width=\"150\">",
"     </col>",
"     <col align=\"center\" width=\"160\">",
"     </col>",
"     <thead valign=\"middle\">",
"      <tr>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Magnesium Salt",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Elemental Magnesium",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         (mg/500 mg salt)",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Magnesium",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         (mEq/500 mg salt)",
"        </p>",
"       </th>",
"      </tr>",
"     </thead>",
"     <tbody valign=\"middle\">",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Magnesium chloride",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         59",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         4.9",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Magnesium gluconate",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         27",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         2.4",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Magnesium L-aspartate",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         49.6",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         4.1",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Magnesium oxide",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         302",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         25",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Magnesium sulfate",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         49.3",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         4.1",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adverse effects associated with elevated serum magnesium concentrations may include:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &gt;3 mg/dL: Blocked peripheral neuromuscular transmission leading to anticonvulsant effects, depressed CNS",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &gt;5 mg/dL: Depressed deep tendon reflexes, flushing, somnolence",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &gt;12 mg/dL: Complete heart block, respiratory paralysis",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12979 Version 38.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-222.190.118.195-6BDFF69EB2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_52_36676=[""].join("\n");
var outline_f35_52_36676=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190866\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1023004\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13291901\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1023018\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190857\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190848\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3416700\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1023005\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190887\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1023006\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3416698\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3416697\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299633\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190855\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3012936\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1023014\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1023016\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3426358\">",
"      Additional Information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12979\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12979|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?34/10/34980?source=related_link\">",
"      Magnesium gluconate: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?40/36/41540?source=related_link\">",
"      Magnesium gluconate: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_52_36677="Dermoscopy vascular structures";
var content_f35_52_36677=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F59688&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F59688&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 566px\">",
"   <div class=\"ttl\">",
"    Morphology of vessels under dermoscopy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 546px; height: 405px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) Dotted and glomerular vessels in string of pearls or serpiginous distribution in a clear cell acanthoma.",
"    <br>",
"     (B) Glomerular vessels focally present at the periphery of a squamous cell carcinoma.",
"     <br>",
"      (C) Polymorphous vessels in a malignant melanoma: dotted and serpentine vessels.",
"      <div class=\"footnotes\">",
"      </div>",
"      <div class=\"reference\">",
"       Reproduced with permission from: Drs. Ashfaq Marghoob and Natalia Jaimes.",
"      </div>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_52_36677=[""].join("\n");
var outline_f35_52_36677=null;
var title_f35_52_36678="Caterpillar bodies";
var content_f35_52_36678=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F83388&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F83388&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Caterpillar bodies in porphyria cutanea tarda and pseudoporphyria",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 363px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Linear arrangement of segmented eosinophilic deposits parallel to the epidermal surface above the subepidermal blister.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Raso DS, Greene WB, Maize JC, et al. Caterpillar bodies of porphyria cutanea tarda ultrastructurally represent a unique arrangement of colloid and basement membrane bodies. Am J Dermatopathol 1996; 18:24. Copyright &copy; 1996 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_52_36678=[""].join("\n");
var outline_f35_52_36678=null;
var title_f35_52_36679="Tenofovir: Pediatric drug information";
var content_f35_52_36679=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Tenofovir: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?18/47/19191?source=see_link\">",
"    see \"Tenofovir: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?36/4/36933?source=see_link\">",
"    see \"Tenofovir: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5709065\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F225434\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Viread&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F855141\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Viread&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1055611\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antiretroviral Agent",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       HIV Agents (Anti-HIV Agents)",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Nucleotide Reverse Transcriptase Inhibitor (NRTI)",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1055605\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?18/47/19191?source=see_link\">",
"      see \"Tenofovir: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Children and Adolescents:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      HIV infection:",
"     </b>",
"     Use in combination with other antiretroviral agents:",
"     <b>",
"      Note:",
"     </b>",
"     Some experts recommend avoiding tenofovir (especially for initial therapy) in prepubertal patients and those in early puberty (Tanner stages 1 and 2), due to concerns about the potential increased risk of bone mineral density loss. Other experts recommend measuring bone mineral density prior to initiation of therapy and 6 months later in these patients [DHHS (pediatric), 2012]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Infants and Children &lt;2 years: Not approved for use; dose is unknown",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Children &ge;2 years and Adolescents; weight &lt;35 kg: Oral: 8 mg/kg/dose once daily; maximum daily dose: 300 mg/",
"     <b>",
"      day",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Dosage form specific:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;\">",
"     <i>",
"      Oral powder:",
"     </i>",
"     <b>",
"      Note:",
"     </b>",
"     One level scoop = 40 mg tenofovir disoproxil fumarate",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:12em;\">",
"     10 to &lt;12 kg: 80 mg (2 scoops) once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:12em;\">",
"     12 to &lt;14 kg: 100 mg (2.5 scoops) once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:12em;\">",
"     14 to &lt;17 kg: 120 mg (3 scoops) once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:12em;\">",
"     17 to &lt;19 kg: 140 mg (3.5 scoops) once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:12em;\">",
"     19 to &lt;22 kg: 160 mg (4 scoops) once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:12em;\">",
"     22 to &lt;24 kg: 180 mg (4.5 scoops)  once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:12em;\">",
"     24 to &lt;27 kg: 200 mg (5 scoops) once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:12em;\">",
"     27 to &lt;29 kg: 220 mg (5.5 scoops) once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:12em;\">",
"     29 to &lt;32 kg: 240 mg (6 scoops) once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:12em;\">",
"     32 to &lt;34 kg: 260 mg (6.5 scoops) once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:12em;\">",
"     34 to &lt;35 kg: 280 mg (7 scoops) once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:12em;\">",
"     &ge;35 kg: 300 mg (7.5 scoops) once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;\">",
"     <i>",
"      Oral tablets:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:12em;\">",
"     17 to &lt;22 kg: 150 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:12em;\">",
"     22 to &lt;28 kg: 200 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:12em;\">",
"     28 to &lt;35 kg: 250 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:12em;\">",
"     &ge;35 kg: 300 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Children &ge;12 years and Adolescents; weight &ge;35 kg: Oral: 300 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Hepatitis B infection, chronic:",
"     </b>",
"     Children and Adolescents &ge;12 years and weight &ge;35 kg: Oral: 300 mg once daily;",
"     <b>",
"      Note:",
"     </b>",
"     Optimal duration of therapy is unknown",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      HIV infection:",
"     </b>",
"     Oral: 300 mg once daily;",
"     <b>",
"      Note:",
"     </b>",
"     Use in combination with other antiretroviral agents",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Hepatitis B infection, chronic:",
"     </b>",
"     Adults: Oral: 300 mg once daily;",
"     <b>",
"      Note:",
"     </b>",
"     Tenofovir is recommended for first-line treatment of HBV (Lok, 2009). Concurrent use with adefovir and/or tenofovir combination products should be avoided.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      Treatment duration (AASLD practice guidelines; Lok, 2009):",
"     </i>",
"     <b>",
"      Note:",
"     </b>",
"     Patients not achieving &lt;2 log decrease in serum HBV DNA after at least 6 months of therapy should either receive additional treatment or be switched to an alternative therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Hepatitis Be antigen (HBeAg) positive chronic hepatitis: Treat &ge;1 year until HBeAg seroconversion and undetectable serum HBV DNA; continue therapy for &ge;6 months after HBeAg seroconversion",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     HBeAg negative chronic hepatitis: Treat &gt;1 year until hepatitis B surface antigen (HB",
"     <sub>",
"      s",
"     </sub>",
"     Ag) clearance",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Decompensated liver disease: Lifelong treatment is recommended",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in renal impairment:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children and Adolescents: There are no dosage adjustments provided in manufacturer&rsquo;s labeling; has not been studied",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: Oral:",
"     <b>",
"      Note:",
"     </b>",
"     Use of powder formulation has not been evaluated in renal impairment. Closely monitor clinical response and renal function in these patients; clinical effectiveness and safety of these guidelines have not been evaluated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &ge;50 mL/minute: No adjustment necessary",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     30-49 mL/minute: 300 mg every 48 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     10-29 mL/minute: 300 mg every 72-96 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute without dialysis: There are no dosage adjustments provided in manufacturer&rsquo;s labeling; has not been studied.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hemodialysis: 300 mg every 7 days or after a total of ~12 hours of dialysis (eg, once weekly with 3 hemodialysis sessions of ~4 hours in length); administer dose after completion of dialysis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in hepatic impairment:",
"     </b>",
"     No dosage adjustment required; in adults, limited number of patients have been studied (especially HBV patients with decompensated liver disease); observe for increased adverse reactions, including renal dysfunction.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F225410\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Powder, oral, as disoproxil fumarate:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Viread&reg;: 40 mg/g (60 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as disoproxil fumarate:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Viread&reg;: 150 mg, 200 mg, 250 mg, 300 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F225396\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1055615\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Powder: Must administer with food. Measure dose only using the supplied dosing scoop. Mix powder well with 2-4 ounces of soft food (applesauce, baby food, yogurt) and swallow immediately (avoids bitter taste); ensure that entire mixture is ingested. Do",
"     <b>",
"      not",
"     </b>",
"     mix in liquid (powder may float on top of the liquid even after stirring).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablets: May be administered without regard to meals",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F6101343\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at 25&deg;C (77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F). Dispense in original container only. Keep container tightly closed.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1055614\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of HIV-1 infection in combination with other antiretroviral agents (FDA approved in ages &ge;2 years and adults);",
"     <b>",
"      Note:",
"     </b>",
"     HIV regimens consisting of three antiretroviral agents are strongly recommended; treatment of chronic hepatitis B virus (HBV) (FDA approved in ages &ge;12 years and adults)",
"    </p>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F225459\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-4em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Chest pain",
"    </p>",
"    <p style=\"text-indent:-4em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Anxiety, depression, dizziness, fatigue, fever, headache, insomnia, pain",
"    </p>",
"    <p style=\"text-indent:-4em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Rash event (includes maculopapular, pustular, or vesiculobullous rash, pruritus or urticaria)",
"    </p>",
"    <p style=\"text-indent:-4em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hyperglycemia, triglycerides increased",
"    </p>",
"    <p style=\"text-indent:-4em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, anorexia, diarrhea, dyspepsia, flatulence, nausea, serum amylase increased, vomiting",
"    </p>",
"    <p style=\"text-indent:-4em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Hematuria",
"    </p>",
"    <p style=\"text-indent:-4em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Neutropenia",
"    </p>",
"    <p style=\"text-indent:-4em;margin-left:4em;text-align:justify;\">",
"     Hepatic: Alkaline phosphatase increased, transaminases increased",
"    </p>",
"    <p style=\"text-indent:-4em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Back pain, creatine kinase increased, myalgia, peripheral neuropathy, weakness",
"    </p>",
"    <p style=\"text-indent:-4em;margin-left:4em;text-align:justify;\">",
"     Renal: Glycosuria, renal failure, serum creatinine increased",
"    </p>",
"    <p style=\"text-indent:-4em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Nasopharyngitis, pneumonia, sinusitis, upper respiratory infection",
"    </p>",
"    <p style=\"text-indent:-4em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Diaphoresis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Acute tubular necrosis, allergic reaction, angioedema, bone mineral density decreased, dyspnea, Fanconi syndrome, hepatic steatosis, hepatitis, hypokalemia, hypophosphatemia, immune reconstitution syndrome, interstitial nephritis, lactic acidosis, muscle weakness, myopathy, nephrogenic diabetes insipidus, nephrotoxicity, osteomalacia, pancreatitis, polyuria, proteinuria, proximal renal tubulopathy, renal insufficiency, renal myopathy, rhabdomyolysis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1055618\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to tenofovir or any component",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1055604\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with hepatic impairment; no dosage adjustment is required; limited studies indicate the pharmacokinetics of tenofovir are not significantly altered in hepatic dysfunction. Limited data exists supporting the treatment of chronic hepatitis B in patients with decompensated liver disease exists; observe for increased adverse reactions, including renal dysfunction.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Do not use concurrently with didanosine for the treatment of HIV infection; didanosine toxicity (including pancreatitis and lactic acidosis) is increased and virologic failures have been reported (DHHS [adult], 2013; [pediatric], 2012).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Fat redistribution and accumulation [ie, central obesity, peripheral wasting, facial wasting, breast enlargement, dorsocervical fat enlargement (buffalo hump), and cushingoid appearance] have been observed in patients receiving antiretroviral agents; causal relationship not established.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Immune  reconstitution syndrome (an acute inflammatory response to residual or indolent opportunistic infections) may occur in HIV patients during initial treatment with combination antiretroviral agents including tenofovir; this syndrome may require further patient assessment and therapy. Autoimmune disorders (eg, Graves&rsquo; disease, polymyositis, and Guillain-Barr&eacute; syndrome) have been reported in patients experiencing immune reconstitution; time to onset is variable and may occur after many months of therapy.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Osteomalacia and reduced bone mineral density (BMD) may occur; long-term effects in humans are not known. Postmarketing cases of osteomalacia which may increase risk of bone fractures have also been reported in association with proximal renal tubulopathy.  Recent studies suggest that tenofovir-related bone loss may be greater in children who are less mature (eg, Tanner stage 1-2) than in those who are more physically mature (Tanner &ge;3). A significant decrease in lumbar spine BMD (&gt;6%) was reported in 5 of 15 pediatric patients who received a tenofovir-containing regimen for 48 weeks. No orthopedic fractures occurred, but two patients required discontinuation of tenofovir. All five patients with a decrease in BMD were virologic responders and prepubertal (Tanner Stage 1). This study found a moderately strong correlation between decreases in bone mineral density z scores at week 48 and age at baseline. No correlation between decreases in bone mineral density z scores and tenofovir dose or pharmacokinetics was observed;  BMD loss may limit the usefulness of tenofovir in prepubertal children [DHHS (pediatric), 2012; Giacomet, 2005; Hazra, 2005; Purdy, 2008]. Monitor BMD for potential bone toxicities during therapy; supplementation with calcium and vitamin D may be beneficial but has not been studied.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     The use of antiretroviral regimens that only contain triple nucleoside reverse transcriptase inhibitors (NRTIs) are generally less effective than regimens containing 2 NRTIs and either an NNRTI or protease inhibitor; use triple NRTI-containing regimens with great caution; early virological failure and high rates of resistance may occur; closely monitor for virologic failure and consider treatment modification.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1055603\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Cases of lactic acidosis, severe hepatomegaly with steatosis and death have been reported in patients receiving tenofovir and other nucleoside analogues",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; most of these cases have been in women; prolonged nucleoside use, obesity, and prior liver disease may be risk factors; use with extreme caution in patients with other risk factors for liver disease; discontinue therapy in patients who develop laboratory or clinical evidence of lactic acidosis or pronounced hepatotoxicity.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     May cause renal toxicity including acute renal failure and/or Fanconi syndrome (renal tubular injury with severe hypophosphatemia); risk may be increased in patients with pre-existing renal disease, underlying systemic disease, or those taking nephrotoxic medications; adults with a low body weight and those taking medications that increase tenofovir serum concentration may also be at increased risk for tenofovir-associated nephrotoxicity; cases of nephrotoxicity have been reported in adolescents receiving tenofovir-containing regimens. Avoid use with concurrent or recent nephrotoxic therapy. Evaluate and monitor renal function, including calculation of creatinine clearance, at baseline and during therapy in all patients receiving tenofovir (regardless of age); monitor serum phosphorus. Dosage adjustment is required in patients with Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;50 mL/minute. Use with caution in patients with low body weight or concurrent medications which increase tenofovir levels.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Severe acute exacerbations of HBV have occurred after tenofovir discontinuation in patients infected with HBV",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; follow hepatic function of HBV-infected patients closely (clinically and with laboratory tests) for at least several months after discontinuing tenofovir therapy; initiate antihepatitis B therapy if needed. Testing for HBV and HIV is recommended prior to the initiation of tenofovir therapy (treatment of HBV in patients with unrecognized/untreated HIV may lead to HIV resistance; treatment of HIV in patients with unrecognized/untreated HBV may lead to rapid HBV resistance). In patients who are coinfected with HIV and HBV, tenofovir should only be used as part of an appropriate combination antiretroviral regimen.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Do not use Viread&reg; (tenofovir) with other tenofovir-containing combination formulations (ie, Atripla&reg;, Complera&trade;, Stribild&trade;, Truvada&reg;). Do not use tenofovir or tenofovir-containing products with adefovir for the treatment of chronic HBV.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F225448\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP1A2 (weak);",
"     <b>",
"      Induces",
"     </b>",
"     P-glycoprotein",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F225404\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acyclovir-Valacyclovir: May decrease the excretion of Tenofovir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adefovir: May diminish the therapeutic effect of Tenofovir. Specifically, adefovir-associated mutations in Hepatitis B viral reverse transcriptase may decrease viral susceptibility to tenofovir. Adefovir may increase the serum concentration of Tenofovir. Tenofovir may increase the serum concentration of Adefovir.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Atazanavir: May increase the serum concentration of Tenofovir. Tenofovir may decrease the serum concentration of Atazanavir. Management: When combined use required, tenofovir 300 mg and atazanavir 300 mg should be used with ritonavir 100 mg (adult doses), all given in single daily dose with food.   Atazanavir without ritonavir should not be used with tenofovir.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dabigatran Etexilate: P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of Dabigatran Etexilate.  Management: Avoid concurrent use of dabigatran with p-glycoprotein inducers when possible.  Closely monitor for decreased levels/effects of dabigatran if concomitantly administering  p-glycoprotein inducers, particularly strong inducers.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Didanosine: Tenofovir may diminish the therapeutic effect of Didanosine. Tenofovir may increase the serum concentration of Didanosine.  Management: Avoid concomitant treatment with tenofovir and didanosine.  Consider altering even existing, stable treatment to avoid this combination.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ganciclovir-Valganciclovir: Tenofovir may increase the serum concentration of Ganciclovir-Valganciclovir. Ganciclovir-Valganciclovir may increase the serum concentration of Tenofovir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Linagliptin: P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of Linagliptin.  Management: Strongly consider using an alternative to any strong P-glycoprotein inducer in patients who are being treated with linagliptin. If this combination is used, monitor patients closely for evidence of reduced linagliptin effectiveness.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lopinavir: May enhance the nephrotoxic effect of Tenofovir. Lopinavir may increase the serum concentration of Tenofovir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Substrates: P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inducers may also further limit the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pomalidomide: P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of Pomalidomide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protease Inhibitors: Tenofovir may decrease the serum concentration of Protease Inhibitors. Protease Inhibitors may increase the serum concentration of Tenofovir.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Saquinavir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: May increase the serum concentration of Tenofovir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     VinCRIStine (Liposomal): P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of VinCRIStine (Liposomal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1055621\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Tablets: A high-fat meal increases oral bioavailability (AUC) by 40% and increases peak serum concentrations by 14%; a light meal had no significant effect on tenofovir pharmacokinetics compared to administration while fasting; food delays the time to peak concentrations by 1 hour",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F225406\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F225420\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were not observed in rat and rabbit reproduction studies. Decreased fetal growth and reduced fetal bone porosity were observed in monkeys. Clinical studies in children have shown bone demineralization with chronic use. Tenofovir crosses the human placenta. No increased risk of overall birth defects has been observed following first trimester exposure according to data collected by the antiretroviral pregnancy registry. Limited data indicate decreased maternal bioavailability during the third trimester. Cases of lactic acidosis/hepatic steatosis syndrome related to mitochondrial toxicity have been reported in pregnant women with prolonged use of nucleoside analogues. It is not known if pregnancy itself potentiates this known side effect; however, women may be at increased risk of lactic acidosis and liver damage. In addition, these adverse events are similar to other rare but life-threatening syndromes which occur during pregnancy (eg HELLP syndrome). Hepatic enzymes and electrolytes should be monitored in women receiving nucleoside analogues and clinicians should watch for early signs of the syndrome. In addition, mitochondrial dysfunction may develop in infants following",
"     <i>",
"      in utero",
"     </i>",
"     exposure. Renal function should also be monitored. The DHHS Perinatal HIV Guidelines consider tenofovir to be an alternative NRTI in dual nucleoside combination regimens. The DHHS Perinatal HIV Guidelines consider emtricitabine plus tenofovir, or lamivudine plus tenofovir as recommended dual NRTI/NtRTI backbones for HIV/HBV coinfected pregnant women. Hepatitis B flare may occur if tenofovir is discontinued postpartum.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Regardless of CD4 count or HIV RNA copy number, all HIV-infected pregnant women should receive a combination antepartum antiretroviral (ARV) drug regimen; this includes women who require therapy for their own health, as well as women who do not yet require therapy for their own health. ARV therapy should be started as soon as possible if required for the woman&rsquo;s health. Although earlier initiation may be more effective in reducing the perinatal transmission of HIV), also consider maternal conditions (eg, nausea and vomiting) and the potential risks of first trimester fetal exposure for specific agents. Plasma HIV RNA levels should be assessed at ~34-36 weeks gestation in order to help determine mode of delivery. If ARV therapy must be interrupted for &lt;24 hours during the peripartum period, stop then restart all medications simultaneously in order to decrease the chance of developing resistance. Long-term follow-up is recommended for all infants exposed to ARV medications.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Healthcare providers are encouraged to enroll pregnant women exposed to antiretroviral medications in the Antiretroviral Pregnancy Registry (1-800-258-4263 or www.APRegistry.com). Healthcare providers caring for HIV-infected women and their infants may contact the National Perinatal HIV Hotline (888-448-8765) for clinical consultation (DHHS [perinatal], 2012).",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1055610\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Hepatitis B, treatment:",
"     </b>",
"     Test patients for HIV prior to starting therapy; CBC with differential, hemoglobin, MCV, reticulocyte count, liver enzymes, bilirubin, renal and hepatic function tests, and HBV RNA plasma levels. Monitor for potential bone and renal abnormalities. Calculate creatinine clearance in all patients prior to starting tenofovir therapy and as clinically needed; monitor for alterations in calculated creatinine clearance and serum phosphorus in patients at risk or with a history of renal dysfunction and patients receiving concurrent nephrotoxic agents. Monitor weight and growth in children. Consider bone mineral density assessment for all patients with a history of pathologic bone fractures or other risk factors for osteoporosis or bone loss. Monitor hepatic function closely (clinically and with laboratory tests) for at least several months after discontinuing tenofovir therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      HIV treatment: Note:",
"     </b>",
"     Monitor CD4 percentage (if &lt;5 years of age) or CD4 count (if &ge;5 years of age) at least every 3-4 months (DHHS [pediatric], 2012). Screen for hepatitis B before starting tenofovir. Also prior to initiation of therapy: Genotypic resistance testing, CD4, viral load, CBC with differential, LFTs, BUN, creatinine. At initiation and with any change in treatment regimen: CBC with differential, electrolytes, calcium, phosphate, glucose, LFTs, bilirubin, BUN, creatinine, albumin, total protein, lipid panel, CD4, and viral load. After 4-8 weeks of therapy: CBC with differential, viral load; then every 3-4 months: CBC with differential, electrolytes, glucose, LFTs, bilirubin, BUN, creatinine, CD4, and viral load. Albumin, total protein, calcium, phosphate, lipid panel and urinalysis every 6-12 months (DHHS [pediatric], 2012). Monitor for signs of opportunistic infections, bone loss, or lactic acidosis.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1055602\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Tenofovir disoproxil fumarate (TDF) is a prodrug of tenofovir;",
"     <i>",
"      in vivo",
"     </i>",
"     , TDF undergoes diester hydrolysis to tenofovir; tenofovir is an acyclic nucleoside phosphate (nucleotide) analog of adenosine 5'-monophosphate; tenofovir undergoes phosphorylation by cellular enzymes to the active tenofovir diphosphate, which serves as an alternative substrate to deoxyadenosine 5'-triphosphate, a natural substrate for cellular DNA polymerase and reverse transcriptase; tenofovir diphosphate inhibits HIV viral reverse transcriptase and HBV polymerase by competing with natural deoxyadenosine 5'-triphosphate and by becoming incorporated into viral DNA causing DNA chain termination.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1055617\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 1.2-1.3 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: Minimal (7.2% to serum proteins)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Not metabolized by CYP isoenzymes; tenofovir disoproxil fumarate (a prodrug) undergoes diester hydrolysis to tenofovir; tenofovir undergoes phosphorylation to the active tenofovir diphosphate",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tablets: 25% (fasting); high-fat meals will increase AUC by 40%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Powder: Peak serum concentrations are 26% lower compared to tablet, but the mean AUCs are similar",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life: Serum: 17 hours; intracellular: 10-50 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: Fasting: 1 hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Excreted via glomerular filtration and active tubular secretion; after I.V. administration: 70% to 80% is excreted in the urine as unchanged drug within 72 hours; after multiple oral doses (administered with food): 32% &plusmn; 10% is excreted in the urine within 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Clearance: Total body clearance is decreased in patients with renal impairment",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dialysis:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hemodialysis: Efficiently removes tenofovir; 4 hours of hemodialysis removed &sim;10% of a single 300 mg dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Peritoneal dialysis: Effects unknown",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1055609\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?36/4/36933?source=see_link\">",
"      see \"Tenofovir: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Tenofovir is not a cure for HIV or HBV; take tenofovir every day as prescribed; do not change dose or discontinue without physician's advice; if a dose is missed, take it as soon as possible, then return to normal dosing schedule; if a dose is skipped, do",
"     <b>",
"      not",
"     </b>",
"     double the next dose; report the use of other medications, nonprescription medications and herbal or natural products to physician and pharmacist; long-term effects are not known; notify physician if persistent severe abdominal pain, nausea, or vomiting occurs",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     HIV medications may cause changes in body fat, including an increase in fat in the upper back and neck, breasts, and trunk; a loss of fat from the face, arms, and legs may also occur. Some HIV medications (including tenofovir) may cause a serious, but rare, condition called lactic acidosis with an increase in liver size (hepatomegaly). Before starting tenofovir, inform physician about other medical conditions, including any liver or kidney problems. Do not take Viread&reg; with other tenofovir-containing medications (eg, Atripla&reg;, Complera&trade;, Stribild&trade;, Truvada&reg;).",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1055619\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Long term studies demonstrating a decrease of clinical progression of HIV in patients receiving tenofovir are needed. Consider tenofovir in patients with HIV strains that would be susceptible as assessed by treatment history or laboratory tests. Mutation of reverse transcriptase at the 65 codon (K65R mutation) confers",
"     <i>",
"      in vitro",
"     </i>",
"     resistance to tenofovir; the K65R mutation is selected in some patients after treatment with didanosine, zalcitabine, or abacavir; thus, cross-resistance may occur. Multiple nucleoside mutations with a T69S double insertion showed decreased",
"     <i>",
"      in vitro",
"     </i>",
"     susceptibility to tenofovir; patients with HIV strains that had &ge;3 zidovudine-associated mutations that included M41L or L210W showed decreased responses to tenofovir (but these responses were still better than placebo); patients with mutations at K65R, or L74V without zidovudine-associated mutations seemed to have a decreased response to tenofovir",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     A high rate of early virologic failure in therapy-naive adult HIV patients has been observed with the once-daily three-drug combination therapy of didanosine enteric-coated beadlets (Videx&reg; EC), lamivudine, and tenofovir and the once-daily three-drug combination therapy of abacavir, lamivudine, and tenofovir. These combinations should not be used as a new treatment regimen for naive or pretreated patients. Any patient currently receiving either of these regimens should be closely monitored for virologic failure and considered for treatment modification. Early virologic failure was also observed in therapy-naive adult HIV patients treated with tenofovir, didanosine enteric-coated beadlets (Videx&reg; EC) and either efavirenz or nevirapine; rapid emergence of resistant mutations has also been reported with this combination; the combination of tenofovir, didanosine, and any non-nucleoside reverse transcriptase inhibitor is",
"     <b>",
"      not",
"     </b>",
"     recommended as initial antiretroviral therapy. Current guidelines warn",
"     <b>",
"      not",
"     </b>",
"     to use tenofovir concurrently with didanosine for the treatment of HIV infection; risk of didanosine toxicity (including pancreatitis and lactic acidosis) is increased and virologic failures have been reported (DHHS, 2011).",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Aberg JA, Kaplan JE, Libman H, et al, \"Primary Care Guidelines for the Management of Persons Infected With Human Immunodeficiency Virus: 2009 Update by the HIV Medicine Association of the Infectious Diseases Society of America,\"",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2009, 49(5):651-81.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/52/36679/abstract-text/19640227/pubmed\" id=\"19640227\" target=\"_blank\">",
"        19640227",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents, &ldquo;Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents, Department of Health and Human Services,&rdquo; February 12, 2013. Available at file://www.aidsinfo.nih.gov",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      DHHS Panel on Antiretroviral Therapy and Medical Management of HIV-Infected Children, \"Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection,\" November 5, 2012. Available at",
"      <a href=\"file://aidsinfo.nih.gov\" target=\"_blank\">",
"       file://aidsinfo.nih.gov",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Giacomet V, Mora S, Martelli L, et al, \"A 12-Month Treatment With Tenofovir Does Not Impair Bone Mineral Accrual in HIV-Infected Children,\"",
"      <i>",
"       J Acquir Immune Defic Syndr",
"      </i>",
"      , 2005, 40(4):448-50.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/52/36679/abstract-text/16280700/pubmed\" id=\"16280700\" target=\"_blank\">",
"        16280700",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hazra R, Balis FM, Tullio AN, et al, &ldquo;Single-Dose and Steady-State Pharmacokinetics of Tenofovir Disoproxil Fumarate in Human Immunodeficiency Virus-Infected Children,&rdquo;",
"      <i>",
"       Antimicrob Agents Chemother",
"      </i>",
"      , 2004, 48(1):124-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/52/36679/abstract-text/14693529/pubmed\" id=\"14693529\" target=\"_blank\">",
"        14693529",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hazra R, Gafni RI, Maldarelli F, et al, \"Tenofovir Disoproxil Fumarate and an Optimized Background Regimen of Antiretroviral Agents as Salvage Therapy for Pediatric HIV Infection,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2005, 116(6):e846-54.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/52/36679/abstract-text/16291735/pubmed\" id=\"16291735\" target=\"_blank\">",
"        16291735",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lok AS and McMahon BJ, \"Chronic Hepatitis B: Update 2009,\"",
"      <i>",
"       Hepatology",
"      </i>",
"      , 2009. Available at file://www.aasld.org/practiceguidelines/Documents/Bookmarked%20Practice%20Guidelines/Chronic_Hep_B_Update_2009%208_24_2009.pdf",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lyseng-Williamson KA, Reynolds NA, and Plosker GL, \"Tenofovir Disoproxil Fumarate: A Review of Its Use in the Management of HIV Infection,\"",
"      <i>",
"       Drugs",
"      </i>",
"      , 2005, 65(3):413-32.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/52/36679/abstract-text/15669881/pubmed\" id=\"15669881\" target=\"_blank\">",
"        15669881",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Purdy JB, Gafni RI, Reynolds JC, et al, \"Decreased Bone Mineral Density With Off-Label Use of Tenofovir in Children and Adolescents Infected With Human Immunodeficiency Virus,\"",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 2008, 152(4):582-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/52/36679/abstract-text/18346519/pubmed\" id=\"18346519\" target=\"_blank\">",
"        18346519",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12824 Version 44.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-122.72.76.133-D52EA7ED9E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_52_36679=[""].join("\n");
var outline_f35_52_36679=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5709065\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225434\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F855141\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055611\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055605\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225410\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225396\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055615\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6101343\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055614\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225459\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055618\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055604\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055603\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225448\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225404\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055621\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225406\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225420\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055610\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055602\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055617\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055609\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055619\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12824\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12824|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?18/47/19191?source=related_link\">",
"      Tenofovir: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?36/4/36933?source=related_link\">",
"      Tenofovir: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_52_36680="Chronic bullous disease of childhood";
var content_f35_52_36680=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F62298%7EDERM%2F76142&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F62298%7EDERM%2F76142&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Linear IgA bullous dermatosis of childhood (chronic bullous disease of childhood)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple tense bullae, crusts, and healing erosions are present. Note the annular configuration of several lesions.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from:",
"     <a href=\"file://www.visualdx.com\" target=\"_blank\">",
"      www.visualdx.com",
"     </a>",
"     . Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Chronic bullous disease of childhood",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from:",
"     <a href=\"file://www.visualdx.com\" target=\"_blank\">",
"      www.visualdx.com",
"     </a>",
"     . Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_52_36680=[""].join("\n");
var outline_f35_52_36680=null;
var title_f35_52_36681="Clinical significance of hepatitis B virus genotypes";
var content_f35_52_36681=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical significance of hepatitis B virus genotypes",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/52/36681/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/52/36681/contributors\">",
"     Chi-Jen Chu, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/52/36681/contributors\">",
"     Anna SF Lok, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/52/36681/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/52/36681/contributors\">",
"     Rafael Esteban, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/52/36681/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/52/36681/contributors\">",
"     Shilpa Grover, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?35/52/36681/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 5, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hepatitis B virus (HBV), a member of the Hepadnaviridae family, replicates asymmetrically via reverse transcription of an RNA intermediate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/52/36681/abstract/1\">",
"     1",
"    </a>",
"    ]. Because the viral polymerase lacks proofreading activity, mutations are common accounting for genetic heterogeneity of HBV. The estimated mutation rate of the hepadnavirus genome is about 2 x 10(4) base",
"    <span class=\"nowrap\">",
"     substitutions/site/year,",
"    </span>",
"    about 100 times higher than that of other DNA viruses but about 100 to 1000 times lower than that of other RNA viruses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/52/36681/abstract/2\">",
"     2",
"    </a>",
"    ]. According to phylogenetic analyses, HBV can be classified into eight genotypes (A to H) based upon an inter-group divergence of 8 percent or more in the complete nucleotide sequence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/52/36681/abstract/3-5\">",
"     3-5",
"    </a>",
"    ]. In the past few years, there is growing evidence suggesting that HBV genotypes influence clinical outcomes, HBeAg seroconversion rates, mutational patterns in the precore and core promoter regions, and response to antiviral therapy. This topic will provide a concise review on the clinical significance of HBV genotypes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevalence of specific genotypes varies geographically [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/52/36681/abstract/4,6,7\">",
"     4,6,7",
"    </a>",
"    ]. Genotype A is found mainly in Northern Europe, North America, India, and Africa, while genotype B and C are prevalent in Asia and genotype D is more common in Southern Europe, the Middle East, and India (",
"    <a class=\"graphic graphic_figure graphicRef68443 \" href=\"mobipreview.htm?11/56/12161\">",
"     figure 1",
"    </a>",
"    ). However, the existing information is still incomplete since data are not available from many parts of the world or are based upon very small numbers of patients.",
"   </p>",
"   <p>",
"    At least two large population-based studies have evaluated the distribution of HBV genotypes in the United States, which are summarized below. Considered together, they suggest that genotypes B and C are most common among those with chronic HBV, while genotype A is most common among those with acute HBV. The preponderance of genotype B and C among those with chronic infection reflects that chronic HBV in the United States is largely due to infection of individuals born elsewhere.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One study (involving 694 patients with chronic HBV from 17 medical centers) identified seven genotypes (A to G) of which genotypes A and C were most common (representing 35 and 31 percent of the cohort, respectively) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/52/36681/abstract/8\">",
"       8",
"      </a>",
"      ]. HBV genotypes B and C accounted for 75 percent of the patients on the west coast, whereas genotypes A and D accounted for 74 percent of the patients in the south. There was a strong correlation between genotype and ethnicity. Genotype A was more common among whites and African Americans, and those with sexually acquired HBV infection while genotypes B and C were seen mostly in Asians, and those who acquired HBV through maternal-infant transmission. This study also underscored the impact of patient migration from Asia on the epidemiology of HBV genotypes in the United States.",
"     </li>",
"     <li>",
"      A later study evaluated 614 patients who developed acute HBV between 1999 and 2005 across six counties [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/52/36681/abstract/9\">",
"       9",
"      </a>",
"      ]. The majority (75 percent) were infected with HBV genotype A, while 18 percent were infected with genotype D. Genotype A infection was much more common among African Americans compared with Hispanics. Genotype A was less common among recent drug users than among non-injection drug users.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     SUBGROUPS",
"    </span>",
"    &nbsp;&mdash;&nbsp;HBV genotypes can be further subdivided based upon their distinct ethnic and geographic origins. Subgroups of genotypes have been reported for most genotypes including A [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/52/36681/abstract/10\">",
"     10",
"    </a>",
"    ], B [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/52/36681/abstract/11,12\">",
"     11,12",
"    </a>",
"    ], and C [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/52/36681/abstract/13,14\">",
"     13,14",
"    </a>",
"    ], although the most detailed findings have been published for genotype B. Two subtypes of genotype B have been identified (Ba and Bj). Genotype Ba arises from a recombination between HBV genotype B and C and has been found in many Asian countries, while genotype Bj (which does not appear to have arisen from recombination with genotype C) is found mainly in Japan [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/52/36681/abstract/11\">",
"     11",
"    </a>",
"    ]. Genotype Ba is more commonly associated with the presence of HBeAg although the role of HBV subgroups in determining clinical outcome remains to be studied [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/52/36681/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. A cross-sectional study from Japan found that fulminant hepatitis was associated with genotype Bj, lack of HBeAg, and high replication due to precore mutants [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/52/36681/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     RECOMBINATION AND COINFECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recombinations between HBV genotypes have been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/52/36681/abstract/16-20\">",
"     16-20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients may be coinfected with more than one genotype. Although the clinical consequences are unclear, antiviral treatment in patients coinfected with more than one genotype may lead to a shift in the predominant genotype [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/52/36681/abstract/21\">",
"     21",
"    </a>",
"    ]. Other reports have demonstrated that infection with HBV genotype G appears to be always associated with genotype A infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/52/36681/abstract/22,23\">",
"     22,23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     RELATIONSHIP OF GENOTYPES TO SEROTYPES",
"    </span>",
"    &nbsp;&mdash;&nbsp;HBV was traditionally classified into four subtypes or serotypes (adr, adw, ayr, and ayw) based upon antigenic determinants of the hepatitis B surface antigen (HBsAg) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/52/36681/abstract/24\">",
"     24",
"    </a>",
"    ]. The common determinant is \"a\" while",
"    <span class=\"nowrap\">",
"     \"d/y\"",
"    </span>",
"    and",
"    <span class=\"nowrap\">",
"     \"r/w\"",
"    </span>",
"    are mutually exclusive sub-determinants. More recently, HBV has been further classified into nine different serotypes (ayw1, ayw2, ayw3, ayw4, ayr, adw2, adw4, adrq+, and adrq-) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/52/36681/abstract/25\">",
"     25",
"    </a>",
"    ]. While several studies have been conducted to investigate the relationship between HBV serotypes and genotypes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/52/36681/abstract/26-29\">",
"     26-29",
"    </a>",
"    ], the results are incomplete because of the limited number of isolates analyzed. In addition, the same serotype may be classified into different genotypes (",
"    <a class=\"graphic graphic_table graphicRef74715 \" href=\"mobipreview.htm?12/28/12747\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/52/36681/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     DETERMINATION OF GENOTYPES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Genotypic differences of HBV can be reflected in a partial sequence of the genome such as the pre-S or S gene [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/52/36681/abstract/3\">",
"     3",
"    </a>",
"    ]. Thus, genotyping can be accomplished without determining the entire genomic sequence. The sequence of the S gene is more conserved and thus more suitable for genotyping than the pre-S region [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/52/36681/abstract/30\">",
"     30",
"    </a>",
"    ]. Several methods have been used for HBV genotyping:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Direct sequencing &mdash; Samples are amplified by polymerase chain reaction (PCR) using primers in the pre-S or S regions, directly sequenced, and the sequences are then compared against published sequences to determine homology with known genotypes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/52/36681/abstract/4,27\">",
"       4,27",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Restriction fragment length polymorphism (RFLP) &mdash; PCR products of HBV S gene containing type-specific regions are digested by restriction enzymes; HBV genotypes can be differentiated based upon difference in sizes of the digested fragments [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/52/36681/abstract/7,30\">",
"       7,30",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Line probe assay &mdash; Amplicons of HBV S gene are hybridized to strips pre-coated with type-specific oligonucleotide probes and HBV genotypes are determined based upon the pattern of reactive bands [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/52/36681/abstract/31,32\">",
"       31,32",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Enzyme-linked immunosorbent assay (ELISA) &mdash; ELISA uses monoclonal antibodies to genotype-specific epitopes of the preS2-region [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/52/36681/abstract/33\">",
"       33",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Genotype-specific PCR [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/52/36681/abstract/34\">",
"       34",
"      </a>",
"      ] or multiplex PCR [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/52/36681/abstract/35\">",
"       35",
"      </a>",
"      ] &mdash; Genotype-specific primers are used for PCR reaction. One study described quantification of HBV DNA and genotyping in a single reaction by real-time PCR and melting curve analysis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/52/36681/abstract/36\">",
"       36",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     GENOTYPES/SEROTYPES-DISEASE PROGRESSION AND HBEAG SEROCONVERSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most of the information on the clinical significance of HBV genotypes has been based upon studies of patients with chronic HBV infection in Asia. Because of the preponderance of genotypes B and C in Asian countries, the studies have generally been restricted to comparisons of patients with these two genotypes (",
"    <a class=\"graphic graphic_table graphicRef63279 \" href=\"mobipreview.htm?3/15/3324\">",
"     table 2",
"    </a>",
"    ). Nevertheless, such comparisons provide important information on the relation between HBV genotype B and C and the rate of progression of liver disease, since the age at the onset of infection is presumed to be the same (perinatal period) in the vast majority of patients.",
"   </p>",
"   <p>",
"    The earliest study done in Japan (involving 1744 patients) found that liver dysfunction (defined as abnormal aminotransferase levels) was observed less frequently in hepatitis B carriers with adw serotype (mainly genotype B) compared to those with adr serotype (mainly genotype C) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/52/36681/abstract/37\">",
"     37",
"    </a>",
"    ]. Several subsequent studies confirmed that compared to genotype C, HBV genotype B is associated with less active liver disease and a slower rate of progression to cirrhosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/52/36681/abstract/38-43\">",
"     38-43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Many cross-sectional studies, mostly in Asian patients, found that the prevalence of HBeAg was higher in patients with genotype C than those with genotype B [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/52/36681/abstract/8,37,38,41,42,44\">",
"     8,37,38,41,42,44",
"    </a>",
"    ]. In addition, several longitudinal follow-up studies showed that the cumulative rate of spontaneous HBeAg seroconversion was significantly higher in patients with genotype B compared to those with genotype C [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/52/36681/abstract/41,44-48\">",
"     41,44-48",
"    </a>",
"    ]. Taken together, these studies showed that spontaneous HBeAg seroconversion occurred earlier and possibly at a higher rate in patients with HBV genotype B than those with genotype C. One study also found that genotype B patients were less likely to have abortive ALT flares before HBeAg seroconversion and more sustained biochemical remission after HBeAg seroconversion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/52/36681/abstract/44\">",
"     44",
"    </a>",
"    ]. A longer duration of high levels of HBV replication may contribute to more active liver disease and, in turn, a higher rate of progression to cirrhosis among patients with HBV genotype C.",
"   </p>",
"   <p>",
"    There is a paucity of data on the clinical course of patients with genotypes other than B and C. Genotypes A and D were found to be prevalent in the Indian subcontinent. In one study genotype D was associated with more severe liver disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/52/36681/abstract/49\">",
"     49",
"    </a>",
"    ]. However, this finding was not confirmed by another study from West India [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/52/36681/abstract/50\">",
"     50",
"    </a>",
"    ]. Another study on 258 Spanish patients with chronic HBV infection (52 percent A, 35 percent D, 7 percent F) found that HBeAg seroconversion rates were similar in patients with genotypes A and D, but sustained biochemical and virological remission was more common in patients with genotype A who had HBeAg seroconversion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/52/36681/abstract/51\">",
"     51",
"    </a>",
"    ]. HBsAg clearance occurred more often in patients with genotype A compared with genotype D, while deaths related to liver disease occurred more often in patients with genotype F. There are several limitations with this study: the number of patients with genotype F was very small and some patients received interferon therapy during the study period. A study from Germany found that genotype D was associated with higher HBV DNA levels than genotype A in children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/52/36681/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There has been no published study comparing the rate of HBeAg seroconversion, activity of liver disease, and rate of progression to cirrhosis among patients with all known HBV genotypes. The lack of such studies is related to the preponderance of 1 or 2 HBV genotypes in most geographical regions. The finding of HBV genotypes A to G in the United States permits studies that compare the clinical course of HBV infection among patients with a wider spectrum of HBV genotypes. In one cross-sectional study of 694 patients in the United States, genotypes B and D were associated with a lower prevalence of HBeAg than genotype A, while genotype B was associated with a lower rate of hepatic decompensation compared to genotype A, C, or D [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/52/36681/abstract/8\">",
"     8",
"    </a>",
"    ]. However, other factors such as differences in",
"    <span class=\"nowrap\">",
"     ethnic/racial",
"    </span>",
"    background, age at onset and duration of infection, and exposures to",
"    <span class=\"nowrap\">",
"     alcohol/environmental",
"    </span>",
"    toxins rather than HBV genotypes may have contributed to the differences in clinical manifestations.",
"   </p>",
"   <p>",
"    A study of 1158 Alaska native persons with chronic HBV infection found that among 507 persons who were initially HBeAg positive, time to spontaneous HBeAg clearance was longest in those with genotype C compared to persons with genotypes A, B, D, or F. Furthermore, genotypes C and F were associated with a higher rate of HBeAg reversion after HBeAg clearance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/52/36681/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Hepatocellular carcinoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies on the relationship between HBV genotypes and hepatocellular carcinoma (HCC) have yielded conflicting results. Several observational studies in East Asia (Japan, China, Hong Kong) and a 2013 meta-analysis have suggested that patients infected with HBV genotype C were more likely to develop HCC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/52/36681/abstract/54-58\">",
"     54-58",
"    </a>",
"    ]. An analysis of a large cohort in Taiwan demonstrated that HBV genotype C and core promoter mutations were independently associated with increased risk of HCC, regardless of HBV DNA levels. Similarly, a study from the United States found that genotype C was associated with HCC in patients awaiting liver transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/52/36681/abstract/59\">",
"     59",
"    </a>",
"    ]. Longitudinal follow-up studies confirmed that HBV genotype C and high serum HBV DNA were independent predictors of HCC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/52/36681/abstract/60-62\">",
"     60-62",
"    </a>",
"    ]. However, some studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/52/36681/abstract/41,45\">",
"     41,45",
"    </a>",
"    ] found that the lifetime risk of cirrhosis and HCC may not differ between patients with genotype B and C but adverse clinical outcomes occur later in patients with genotype B.",
"   </p>",
"   <p>",
"    The major discrepant findings came from studies in Taiwan demonstrating that genotype B was more common than genotype C in younger (&lt;35 years old) non-cirrhotic patients with HCC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/52/36681/abstract/39,48,63\">",
"     39,48,63",
"    </a>",
"    ]. The discrepancy cannot be explained by different geographic distribution of genotype B subgroups (Ba and Bj) because studies from China and Hong Kong where the predominant subgroup is also Ba found that patients with genotype B had lower risk of HCC than those with genotype C.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Chronicity of infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several reports raised suspicion that HBV genotypes vary in their ability to induce chronic infection. Two studies from Japan with 57 and 53 cases of acute hepatitis supported the hypothesis that genotype A more often progressed to chronicity than genotype C [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/52/36681/abstract/64-66\">",
"     64-66",
"    </a>",
"    ]. Similar finding from Switzerland suggested that progression from acute to chronic hepatitis B was more likely with genotype A compared to genotype D [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/52/36681/abstract/67\">",
"     67",
"    </a>",
"    ]. Larger-scaled studies are needed to confirm these findings.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Fulminant hepatitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Due to the rarity of the illness and the frequent absence of detectable serum HBV DNA at presentation, it has been difficult to investigate the role of HBV genotypes in fulminant hepatitis. One study reported that an outbreak of fulminant hepatitis in the United States was associated with genotype D [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/52/36681/abstract/68\">",
"     68",
"    </a>",
"    ]. Unfortunately, this study lacked a proper control group to establish any causal link and other factors such as HCV coinfection, and heavy exposure to alcohol,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    , and injected methamphetamine or cocaine rather than viral factors may be responsible for the fulminant course. A more comprehensive study by the United States Acute Liver Failure Study Group comparing 34 patients with HBV-related acute liver failure with a cohort of 530 patients with chronic HBV infection showed a higher prevalence of genotype D in the acute liver failure group (32 versus 16 percent) even after matching for race and HBeAg status [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/52/36681/abstract/69\">",
"     69",
"    </a>",
"    ]. The above results indicated that HBV genotypes may have a role in the outcome of acute infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     SERUM QUANTITATIVE HBV DNA LEVELS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies on the relation between HBV genotypes and HBV DNA levels have yielded conflicting results. A study of blood donors found that patients with genotype C had higher serum HBV DNA levels than those with genotype B [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/52/36681/abstract/70\">",
"     70",
"    </a>",
"    ]. In contrast, two retrospective studies reported that serum HBV DNA levels were comparable between patients with genotype B and C, regardless of HBeAg status [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/52/36681/abstract/41,45\">",
"     41,45",
"    </a>",
"    ]. The United States nationwide study found that serum HBV DNA levels were comparable among the major genotypes (A to D) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/52/36681/abstract/8\">",
"     8",
"    </a>",
"    ]. However, HBV DNA levels were tested at one time point only. Thus, a relation between HBV genotypes and serum HBV DNA levels cannot be definitively excluded. Another study that focused on 694 patients who had participated in phase III trials of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/44/10949?source=see_link\">",
"     adefovir",
"    </a>",
"    dipivoxil found that among HBeAg-positive patients, those infected with genotype C had significantly lower HBV DNA levels while among HBeAg-negative patients, those infected with genotype D had significantly higher HBV DNA levels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/52/36681/abstract/71\">",
"     71",
"    </a>",
"    ]. It should be emphasized that patients in this study were participants of a clinical trial on antiviral therapy and may not be representative of patients with chronic HBV infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     PRECORE VARIANTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mutations in the precore region of the HBV genome have been described in many HBeAg-negative patients who have persistent viremia and active liver disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/52/36681/abstract/72-74\">",
"     72-74",
"    </a>",
"    ]. The predominant mutation involves a G to A change at nucleotide 1896 (G1896A), which creates a premature stop codon (eW28X). This mutation prevents translation of the precore protein and completely abolishes the production of HBeAg. Nucleotide 1896 is engaged in the formation of a stem-loop structure, epsilon, which is required for the encapsidation of the pregenomic RNA into the nucleocapsid for completion of the viral replication cycle [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/52/36681/abstract/75\">",
"     75",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/35/21045?source=see_link\">",
"     \"Characteristics of the hepatitis B virus and pathogenesis of infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Selection of the G1896A mutation is genotype-dependent and is more likely to occur when the nucleotide at the opposite position of the stem (nucleotide 1858) in the stem-loop structure of epsilon, the pregenome encapsidation signal, is T rather than C [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/52/36681/abstract/76-78\">",
"     76-78",
"    </a>",
"    ]. This may explain why HBeAg-negative chronic hepatitis B and the common precore variant G1896A are less frequently encountered in the United States and Northern Europe where genotype A (which almost always has a C at nucleotide 1858) is more common [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/52/36681/abstract/7,32,77,78\">",
"     7,32,77,78",
"    </a>",
"    ]. In contrast, in other parts of the world with a higher prevalence of precore mutants (such as Asia and the Mediterranean basin), HBV genotypes B, C, and D (which frequently have a T nucleotide at 1858) predominate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/52/36681/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Two studies from Spain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/52/36681/abstract/78\">",
"     78",
"    </a>",
"    ] and France [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/52/36681/abstract/32\">",
"     32",
"    </a>",
"    ] involving 42 and 151 patients with chronic HBV infection, respectively, found that the precore variant was most common among patients with genotype D (65 to 75 percent) and least common among patients with genotype A (9 to 18 percent). Most studies showed precore variant is more commonly associated with genotype B than C [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/52/36681/abstract/38,41,42,79\">",
"     38,41,42,79",
"    </a>",
"    ]. The nationwide study in the United States found that precore variant was detected in 3, 46, 24, and 73 percent of patients with genotype A, B, C and D, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/52/36681/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     CORE PROMOTER VARIANTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The basal core promoter region (nucleotides 1742 to 1849) and the core upstream regulatory sequences (nucleotides 1643 to 1742) are located upstream of the precore region (nucleotides 1814 to 1901), and have an important role in HBV replication and HBeAg production [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/52/36681/abstract/80\">",
"     80",
"    </a>",
"    ]. Mutations in these regions downregulate precore mRNA transcription and HBeAg synthesis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/52/36681/abstract/81,82\">",
"     81,82",
"    </a>",
"    ]. The most common core promoter variant involves a 2-nucleotide substitution: A to T at nucleotide 1762 and G to A at nucleotide 1764 (A1762T, G1764A) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/52/36681/abstract/83-85\">",
"     83-85",
"    </a>",
"    ]. These changes were initially thought to be related to a \"HBeAg-negative phenotype\" but more recent studies showed that they can also be found in some HBeAg-positive patients, especially those with chronic hepatitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/52/36681/abstract/83,86\">",
"     83,86",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical and virologic significance of the basal core promoter mutations are not yet fully understood. Some [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/52/36681/abstract/81,87,88\">",
"     81,87,88",
"    </a>",
"    ] but not all [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/52/36681/abstract/89\">",
"     89",
"    </a>",
"    ] in vitro studies suggested that these changes may increase HBV replication. The core promoter variant has been associated with more severe liver damage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/52/36681/abstract/38,42,84,90,91\">",
"     38,42,84,90,91",
"    </a>",
"    ] and HCC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/52/36681/abstract/57,91-93\">",
"     57,91-93",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is growing evidence that the prevalence of the core promoter variant varies among different HBV genotypes. Several studies found that the core promoter variant is more often detected in patients with HBV genotypes that preclude the selection of the precore variant [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/52/36681/abstract/94,95\">",
"     94,95",
"    </a>",
"    ]. Studies from Asia suggested that the dual core promoter variant (A1762T, G1764A) was more common in patients with genotype C than those with genotype B [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/52/36681/abstract/38,42\">",
"     38,42",
"    </a>",
"    ]. The United States nationwide study reported that the prevalence of core promoter variant among patients with genotype A, B, C and D were 41, 27, 60, and 42 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/52/36681/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     RESPONSES TO INTERFERON",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of reports have suggested that the response rate to interferon (IFN) therapy may be different among HBV genotypes.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Genotype B versus C: One study involving 58 patients in Taiwan found that the rate of HBeAg loss was significantly higher in patients with genotype B compared to those with genotype C (41 versus 15 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/52/36681/abstract/96\">",
"       96",
"      </a>",
"      ]. Similar conclusions were reached in a report that included 109 Chinese patients from Hong Kong (HBeAg clearance of 39 versus 17 percent for genotypes B versus C, respectively) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/52/36681/abstract/97\">",
"       97",
"      </a>",
"      ]. Multivariate analysis showed that genotype B and lower pretreatment HBV DNA levels were independent predictors of antiviral response. Genotype A versus D: A study of 144 German patients (99 of them were HBeAg positive) found that the response rate to standard IFN therapy was higher among patients with genotype A than in those with genotype D, in both HBeAg-positive (46 versus 24 percent) and HBeAg-negative (59 versus 29 percent) patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/52/36681/abstract/98\">",
"       98",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Four major genotypes (A to D): A multinational trial included 266 patients with HBeAg-positive HBV who were randomly assigned to peginterferon alfa-2b alone or in combination with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/7/38007?source=see_link\">",
"       lamivudine",
"      </a>",
"      for 52 weeks [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/52/36681/abstract/99\">",
"       99",
"      </a>",
"      ]. HBeAg loss was significantly higher for genotype A versus D (47 versus 25 percent) and for genotype B versus C (44 versus 28 percent). Genotype was an independent predictor of HBeAg loss on multivariate analysis. The rate of HBsAg seroconversion also differed according to genotype being significantly higher with genotype A versus D (13 versus 2 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/52/36681/abstract/100\">",
"       100",
"      </a>",
"      ]. Follow-up of these patients up to 3.5 years after stopping treatment showed that initial responders (HBeAg loss 26 weeks after stopping treatment) with genotype A were more likely to have a sustained response compared to patients with other genotypes sustained HBeAg loss was seen in 96 versus 76 percent, HBV DNA &lt;400",
"      <span class=\"nowrap\">",
"       copies/mL",
"      </span>",
"      in 65 versus 27 percent, and HBsAg loss in 28 versus 3 percent of patients with genotype A versus non-A, respectively [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/52/36681/abstract/101\">",
"       101",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?13/60/14281?source=see_link\">",
"       \"Standard and pegylated interferon for chronic hepatitis B virus infection\"",
"      </a>",
"      .) Another study enrolling 814 HBeAg-positive patients found there were no differences in response rates between four major genotypes treated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/27/27064?source=see_link\">",
"       pegylated interferon alfa-2a",
"      </a>",
"      , lamivudine, or combination therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/52/36681/abstract/102\">",
"       102",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Regarding the impact of HBV genotypes on sustained response in HBeAg-negative patients, retrospective analysis of 518 patients in a trial comparing 48 weeks of peginterferon alfa-2a alone,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/7/38007?source=see_link\">",
"       lamivudine",
"      </a>",
"      alone, or combination of peginterferon alfa-2a and lamivudine found that, compared with genotype D, patients with genotype B (odds ratio: 3.69, P=0.003) or genotype C (odds ratio: 5.46, P&lt;0.001) were more likely to achieve ALT normalization and HBV DNA &lt;2x10(4)",
"      <span class=\"nowrap\">",
"       copies/mL",
"      </span>",
"      one year after completion of treatment [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/52/36681/abstract/103\">",
"       103",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     RESPONSES TO LAMIVUDINE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The correlation between HBV genotype and response to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    has not been well-established.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Genotype B versus C: Several studies in Asia, all involving small numbers of patients and varying duration of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/7/38007?source=see_link\">",
"       lamivudine",
"      </a>",
"      treatment, showed that HBeAg seroconversion occurred in similar proportions of patients with genotypes B and C [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/52/36681/abstract/104,105\">",
"       104,105",
"      </a>",
"      ]. The incidence of virological breakthrough and the patterns of mutations in the YMDD locus seemed unrelated to HBV genotypes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/52/36681/abstract/104-107\">",
"       104-107",
"      </a>",
"      ]. However, two studies, one in HBeAg-positive and one in HBeAg-negative patients found that patients with genotype B were more likely to sustain their response than genotype C when treatment was discontinued [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/52/36681/abstract/108,109\">",
"       108,109",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Genotype A versus D: One study found that patients with adw serotype (mainly genotype A) were more likely to develop resistance to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/7/38007?source=see_link\">",
"       lamivudine",
"      </a>",
"      than those with ayw serotype (mainly genotype D) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/52/36681/abstract/110\">",
"       110",
"      </a>",
"      ]. However, this study was based upon only 26 patients. Studies from Italy and Germany found lamivudine-resistant mutants may emerge more rapidly in those with genotype A versus D, but a correlation with response was not reported [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/52/36681/abstract/111,112\">",
"       111,112",
"      </a>",
"      ]. A study involving 76 Indian patients showed genotype D achieved higher rate of sustained virological response than genotype A (29 versus 4 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/52/36681/abstract/113\">",
"       113",
"      </a>",
"      ]. However, the result was based upon a 12-month duration of therapy and heterogeneous (45 HBeAg-positive and 31 HBeAg-negative) study population.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     RESPONSE TO ADEFOVIR DIPIVOXIL",
"    </span>",
"    &nbsp;&mdash;&nbsp;The relation between HBV genotype and response to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/44/10949?source=see_link\">",
"     adefovir",
"    </a>",
"    dipivoxil was studied in 694 patients who participated in the phase III trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/52/36681/abstract/71\">",
"     71",
"    </a>",
"    ]. HBV DNA reduction and HBeAg seroconversion occurred in similar proportions of patients with genotypes A to D at the end of 48-week treatment. However, this study combined HBeAg-positive and HBeAg-negative patients and did not provide data on durability of treatment response. In addition, the number of patients with HBeAg seroconversion was too small for a definitive conclusion on the relation between HBV genotype and adefovir-related HBeAg seroconversion. In another report, development of adefovir resistance was associated with genotype D [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/52/36681/abstract/114\">",
"     114",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     RESPONSE TO ENTECAVIR OR TELBIVUDINE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The impact of HBV genotypes on drug resistance to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/55/29557?source=see_link\">",
"     entecavir",
"    </a>",
"    has been evaluated in",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    -refractory patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/52/36681/abstract/115\">",
"     115",
"    </a>",
"    ]. The HBV genotype was not an independent factor of virological breakthrough. A clinical trial enrolling 458 HBeAg-positive and 222 HBeAg-negative patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/52/36681/abstract/116\">",
"     116",
"    </a>",
"    ] who received two years of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/15/3317?source=see_link\">",
"     telbivudine",
"    </a>",
"    showed that HBeAg seroconversion, ALT normalization, and HBV DNA negativity by PCR were comparable among the four major genotypes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     RECURRENCE AFTER TRANSPLANTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A pilot study suggested that patients infected with genotype D may be at increased risk for the development of HBV recurrence following liver transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/52/36681/abstract/117\">",
"     117",
"    </a>",
"    ]. Different conclusions were reached in a second report, which found no association between genotypes A or D and recurrence or any other clinical outcomes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/52/36681/abstract/118\">",
"     118",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Growing evidence suggests that hepatitis B virus (HBV) genotypes may influence HBeAg seroconversion rates, mutational patterns in the precore and core promoter regions, severity of liver disease, and response to interferon treatment. However, the role of HBV genotyping in guiding clinical decisions requires further study before it can be recommended routinely.",
"   </p>",
"   <p>",
"    Because different HBV genotypes predominate in various parts of the world, the heterogeneity in disease manifestations and response to antiviral treatment among patients with chronic hepatitis B in different parts of the world may, at least in part, be attributed to differences in HBV genotypes. Despite increasing knowledge on the clinical relevance of HBV genotypes, routine testing for HBV genotypes in clinical practice is not warranted except for HBeAg-positive patients who are contemplating interferon therapy because of a much higher rate of HBeAg and HBsAg loss in those with genotype A.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/52/36681/abstract/1\">",
"      Summers J, Mason WS. Replication of the genome of a hepatitis B--like virus by reverse transcription of an RNA intermediate. Cell 1982; 29:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/52/36681/abstract/2\">",
"      Girones R, Miller RH. Mutation rate of the hepadnavirus genome. Virology 1989; 170:595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/52/36681/abstract/3\">",
"      Norder H, Courouc&eacute; AM, Magnius LO. Complete genomes, phylogenetic relatedness, and structural proteins of six strains of the hepatitis B virus, four of which represent two new genotypes. Virology 1994; 198:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/52/36681/abstract/4\">",
"      Stuyver L, De Gendt S, Van Geyt C, et al. A new genotype of hepatitis B virus: complete genome and phylogenetic relatedness. J Gen Virol 2000; 81:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/52/36681/abstract/5\">",
"      Arauz-Ruiz P, Norder H, Robertson BH, Magnius LO. Genotype H: a new Amerindian genotype of hepatitis B virus revealed in Central America. J Gen Virol 2002; 83:2059.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/52/36681/abstract/6\">",
"      Norder H, Hammas B, Lee SD, et al. Genetic relatedness of hepatitis B viral strains of diverse geographical origin and natural variations in the primary structure of the surface antigen. J Gen Virol 1993; 74 ( Pt 7):1341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/52/36681/abstract/7\">",
"      Lindh M, Andersson AS, Gusdal A. Genotypes, nt 1858 variants, and geographic origin of hepatitis B virus--large-scale analysis using a new genotyping method. J Infect Dis 1997; 175:1285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/52/36681/abstract/8\">",
"      Chu CJ, Keeffe EB, Han SH, et al. Hepatitis B virus genotypes in the United States: results of a nationwide study. Gastroenterology 2003; 125:444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/52/36681/abstract/9\">",
"      Teshale EH, Ramachandran S, Xia GL, et al. Genotypic distribution of hepatitis B virus (HBV) among acute cases of HBV infection, selected United States counties, 1999-2005. Clin Infect Dis 2011; 53:751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/52/36681/abstract/10\">",
"      Sugauchi F, Kumada H, Acharya SA, et al. Epidemiological and sequence differences between two subtypes (Ae and Aa) of hepatitis B virus genotype A. J Gen Virol 2004; 85:811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/52/36681/abstract/11\">",
"      Sugauchi F, Orito E, Ichida T, et al. Epidemiologic and virologic characteristics of hepatitis B virus genotype B having the recombination with genotype C. Gastroenterology 2003; 124:925.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/52/36681/abstract/12\">",
"      Kobayashi M, Suzuki F, Akuta N, et al. Virological differences between patients infected with subtypes Ba and Bj of hepatitis B virus genotype B. J Gastroenterol Hepatol 2005; 20:570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/52/36681/abstract/13\">",
"      Huy TT, Ushijima H, Quang VX, et al. Genotype C of hepatitis B virus can be classified into at least two subgroups. J Gen Virol 2004; 85:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/52/36681/abstract/14\">",
"      Chan HL, Tsui SK, Tse CH, et al. Epidemiological and virological characteristics of 2 subgroups of hepatitis B virus genotype C. J Infect Dis 2005; 191:2022.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/52/36681/abstract/15\">",
"      Ozasa A, Tanaka Y, Orito E, et al. Influence of genotypes and precore mutations on fulminant or chronic outcome of acute hepatitis B virus infection. Hepatology 2006; 44:326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/52/36681/abstract/16\">",
"      Bollyky PL, Rambaut A, Harvey PH, Holmes EC. Recombination between sequences of hepatitis B virus from different genotypes. J Mol Evol 1996; 42:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/52/36681/abstract/17\">",
"      Morozov V, Pisareva M, Groudinin M. Homologous recombination between different genotypes of hepatitis B virus. Gene 2000; 260:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/52/36681/abstract/18\">",
"      Bowyer SM, Sim JG. Relationships within and between genotypes of hepatitis B virus at points across the genome: footprints of recombination in certain isolates. J Gen Virol 2000; 81:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/52/36681/abstract/19\">",
"      Wang Z, Liu Z, Zeng G, et al. A new intertype recombinant between genotypes C and D of hepatitis B virus identified in China. J Gen Virol 2005; 86:985.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/52/36681/abstract/20\">",
"      Kurbanov F, Tanaka Y, Fujiwara K, et al. A new subtype (subgenotype) Ac (A3) of hepatitis B virus and recombination between genotypes A and E in Cameroon. J Gen Virol 2005; 86:2047.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/52/36681/abstract/21\">",
"      Hannoun C, Krogsgaard K, Horal P, et al. Genotype mixtures of hepatitis B virus in patients treated with interferon. J Infect Dis 2002; 186:752.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/52/36681/abstract/22\">",
"      Kato H, Orito E, Gish RG, et al. Hepatitis B e antigen in sera from individuals infected with hepatitis B virus of genotype G. Hepatology 2002; 35:922.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/52/36681/abstract/23\">",
"      Kremsdorf D, Garreau F, Capel F, et al. In vivo selection of a hepatitis B virus mutant with abnormal viral protein expression. J Gen Virol 1996; 77 ( Pt 5):929.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/52/36681/abstract/24\">",
"      Mazzur S, Burgert S, Blumberg BS. Geographical distribution of Australia antigen determinants d, y and w. Nature 1974; 247:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/52/36681/abstract/25\">",
"      Courouc&eacute;-Pauty AM, Lemaire JM, Roux JF. New hepatitis B surface antigen subtypes inside the ad category. Vox Sang 1978; 35:304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/52/36681/abstract/26\">",
"      Okamoto H, Tsuda F, Sakugawa H, et al. Typing hepatitis B virus by homology in nucleotide sequence: comparison of surface antigen subtypes. J Gen Virol 1988; 69 ( Pt 10):2575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/52/36681/abstract/27\">",
"      Norder H, Hammas B, L&ouml;fdahl S, et al. Comparison of the amino acid sequences of nine different serotypes of hepatitis B surface antigen and genomic classification of the corresponding hepatitis B virus strains. J Gen Virol 1992; 73 ( Pt 5):1201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/52/36681/abstract/28\">",
"      Norder H, Courouc&eacute; AM, Magnius LO. Molecular basis of hepatitis B virus serotype variations within the four major subtypes. J Gen Virol 1992; 73 ( Pt 12):3141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/52/36681/abstract/29\">",
"      Norder H, Courouc&eacute; AM, Coursaget P, et al. Genetic diversity of hepatitis B virus strains derived worldwide: genotypes, subgenotypes, and HBsAg subtypes. Intervirology 2004; 47:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/52/36681/abstract/30\">",
"      Mizokami M, Nakano T, Orito E, et al. Hepatitis B virus genotype assignment using restriction fragment length polymorphism patterns. FEBS Lett 1999; 450:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/52/36681/abstract/31\">",
"      Grandjacques C, Pradat P, Stuyver L, et al. Rapid detection of genotypes and mutations in the pre-core promoter and the pre-core region of hepatitis B virus genome: correlation with viral persistence and disease severity. J Hepatol 2000; 33:430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/52/36681/abstract/32\">",
"      Hussain M, Chu CJ, Sablon E, Lok AS. Rapid and sensitive assays for determination of hepatitis B virus (HBV) genotypes and detection of HBV precore and core promoter variants. J Clin Microbiol 2003; 41:3699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/52/36681/abstract/33\">",
"      Usuda S, Okamoto H, Iwanari H, et al. Serological detection of hepatitis B virus genotypes by ELISA with monoclonal antibodies to type-specific epitopes in the preS2-region product. J Virol Methods 1999; 80:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/52/36681/abstract/34\">",
"      Naito H, Hayashi S, Abe K. Rapid and specific genotyping system for hepatitis B virus corresponding to six major genotypes by PCR using type-specific primers. J Clin Microbiol 2001; 39:362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/52/36681/abstract/35\">",
"      Kirschberg O, Sch&uuml;ttler C, Repp R, Schaefer S. A multiplex-PCR to identify hepatitis B virus--enotypes A-F. J Clin Virol 2004; 29:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/52/36681/abstract/36\">",
"      Yeh SH, Tsai CY, Kao JH, et al. Quantification and genotyping of hepatitis B virus in a single reaction by real-time PCR and melting curve analysis. J Hepatol 2004; 41:659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/52/36681/abstract/37\">",
"      Shiina S, Fujino H, Uta Y, et al. Relationship of HBsAg subtypes with HBeAg/anti-HBe status and chronic liver disease. Part I: Analysis of 1744 HBsAg carriers. Am J Gastroenterol 1991; 86:866.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/52/36681/abstract/38\">",
"      Lindh M, Hannoun C, Dhillon AP, et al. Core promoter mutations and genotypes in relation to viral replication and liver damage in East Asian hepatitis B virus carriers. J Infect Dis 1999; 179:775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/52/36681/abstract/39\">",
"      Kao JH, Chen PJ, Lai MY, Chen DS. Hepatitis B genotypes correlate with clinical outcomes in patients with chronic hepatitis B. Gastroenterology 2000; 118:554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/52/36681/abstract/40\">",
"      Chu CM, Liaw YF. Genotype C hepatitis B virus infection is associated with a higher risk of reactivation of hepatitis B and progression to cirrhosis than genotype B: a longitudinal study of hepatitis B e antigen-positive patients with normal aminotransferase levels at baseline. J Hepatol 2005; 43:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/52/36681/abstract/41\">",
"      Sumi H, Yokosuka O, Seki N, et al. Influence of hepatitis B virus genotypes on the progression of chronic type B liver disease. Hepatology 2003; 37:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/52/36681/abstract/42\">",
"      Orito E, Mizokami M, Sakugawa H, et al. A case-control study for clinical and molecular biological differences between hepatitis B viruses of genotypes B and C. Japan HBV Genotype Research Group. Hepatology 2001; 33:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/52/36681/abstract/43\">",
"      Chan HL, Wong GL, Tse CH, et al. Hepatitis B virus genotype C is associated with more severe liver fibrosis than genotype B. Clin Gastroenterol Hepatol 2009; 7:1361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/52/36681/abstract/44\">",
"      Chu CJ, Hussain M, Lok AS. Hepatitis B virus genotype B is associated with earlier HBeAg seroconversion compared with hepatitis B virus genotype C. Gastroenterology 2002; 122:1756.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/52/36681/abstract/45\">",
"      Yuen MF, Sablon E, Yuan HJ, et al. Significance of hepatitis B genotype in acute exacerbation, HBeAg seroconversion, cirrhosis-related complications, and hepatocellular carcinoma. Hepatology 2003; 37:562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/52/36681/abstract/46\">",
"      Nakayoshi T, Maeshiro T, Nakayoshi T, et al. Difference in prognosis between patients infected with hepatitis B virus with genotype B and those with genotype C in the Okinawa Islands: a prospective study. J Med Virol 2003; 70:350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/52/36681/abstract/47\">",
"      Kao JH, Chen PJ, Lai MY, Chen DS. Hepatitis B virus genotypes and spontaneous hepatitis B e antigen seroconversion in Taiwanese hepatitis B carriers. J Med Virol 2004; 72:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/52/36681/abstract/48\">",
"      Ni YH, Chang MH, Wang KJ, et al. Clinical relevance of hepatitis B virus genotype in children with chronic infection and hepatocellular carcinoma. Gastroenterology 2004; 127:1733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/52/36681/abstract/49\">",
"      Thakur V, Guptan RC, Kazim SN, et al. Profile, spectrum and significance of HBV genotypes in chronic liver disease patients in the Indian subcontinent. J Gastroenterol Hepatol 2002; 17:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/52/36681/abstract/50\">",
"      Gandhe SS, Chadha MS, Arankalle VA. Hepatitis B virus genotypes and serotypes in western India: lack of clinical significance. J Med Virol 2003; 69:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/52/36681/abstract/51\">",
"      S&aacute;nchez-Tapias JM, Costa J, Mas A, et al. Influence of hepatitis B virus genotype on the long-term outcome of chronic hepatitis B in western patients. Gastroenterology 2002; 123:1848.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/52/36681/abstract/52\">",
"      Oommen PT, Wirth S, Wintermeyer P, Gerner P. Relationship between viral load and genotypes of hepatitis B virus in children with chronic hepatitis B. J Pediatr Gastroenterol Nutr 2006; 43:342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/52/36681/abstract/53\">",
"      Livingston SE, Simonetti JP, Bulkow LR, et al. Clearance of hepatitis B e antigen in patients with chronic hepatitis B and genotypes A, B, C, D, and F. Gastroenterology 2007; 133:1452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/52/36681/abstract/54\">",
"      Orito E, Ichida T, Sakugawa H, et al. Geographic distribution of hepatitis B virus (HBV) genotype in patients with chronic HBV infection in Japan. Hepatology 2001; 34:590.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/52/36681/abstract/55\">",
"      Fujie H, Moriya K, Shintani Y, et al. Hepatitis B virus genotypes and hepatocellular carcinoma in Japan. Gastroenterology 2001; 120:1564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/52/36681/abstract/56\">",
"      Ding X, Mizokami M, Yao G, et al. Hepatitis B virus genotype distribution among chronic hepatitis B virus carriers in Shanghai, China. Intervirology 2001; 44:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/52/36681/abstract/57\">",
"      Yang HI, Yeh SH, Chen PJ, et al. Associations between hepatitis B virus genotype and mutants and the risk of hepatocellular carcinoma. J Natl Cancer Inst 2008; 100:1134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/52/36681/abstract/58\">",
"      Wong GL, Chan HL, Yiu KK, et al. Meta-analysis: The association of hepatitis B virus genotypes and hepatocellular carcinoma. Aliment Pharmacol Ther 2013; 37:517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/52/36681/abstract/59\">",
"      Gaglio P, Singh S, Degertekin B, et al. Impact of the hepatitis B virus genotype on pre- and post-liver transplantation outcomes. Liver Transpl 2008; 14:1420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/52/36681/abstract/60\">",
"      Chan HL, Hui AY, Wong ML, et al. Genotype C hepatitis B virus infection is associated with an increased risk of hepatocellular carcinoma. Gut 2004; 53:1494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/52/36681/abstract/61\">",
"      Yu MW, Yeh SH, Chen PJ, et al. Hepatitis B virus genotype and DNA level and hepatocellular carcinoma: a prospective study in men. J Natl Cancer Inst 2005; 97:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/52/36681/abstract/62\">",
"      Mahmood S, Niiyama G, Kamei A, et al. Influence of viral load and genotype in the progression of Hepatitis B-associated liver cirrhosis to hepatocellular carcinoma. Liver Int 2005; 25:220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/52/36681/abstract/63\">",
"      Chen CH, Eng HL, Lee CM, et al. Correlations between hepatitis B virus genotype and cirrhotic or non-cirrhotic hepatoma. Hepatogastroenterology 2004; 51:552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/52/36681/abstract/64\">",
"      Kobayashi M, Arase Y, Ikeda K, et al. Clinical characteristics of patients infected with hepatitis B virus genotypes A, B, and C. J Gastroenterol 2002; 37:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/52/36681/abstract/65\">",
"      Kobayashi M, Arase Y, Ikeda K, et al. Clinical features of hepatitis B virus genotype A in Japanese patients. J Gastroenterol 2003; 38:656.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/52/36681/abstract/66\">",
"      Suzuki Y, Kobayashi M, Ikeda K, et al. Persistence of acute infection with hepatitis B virus genotype A and treatment in Japan. J Med Virol 2005; 76:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/52/36681/abstract/67\">",
"      Mayerat C, Mantegani A, Frei PC. Does hepatitis B virus (HBV) genotype influence the clinical outcome of HBV infection? J Viral Hepat 1999; 6:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/52/36681/abstract/68\">",
"      Garfein RS, Bower WA, Loney CM, et al. Factors associated with fulminant liver failure during an outbreak among injection drug users with acute hepatitis B. Hepatology 2004; 40:865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/52/36681/abstract/69\">",
"      Wai CT, Fontana RJ, Polson J, et al. Clinical outcome and virological characteristics of hepatitis B-related acute liver failure in the United States. J Viral Hepat 2005; 12:192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/52/36681/abstract/70\">",
"      Kao JH, Chen PJ, Lai MY, Chen DS. Clinical and virological aspects of blood donors infected with hepatitis B virus genotypes B and C. J Clin Microbiol 2002; 40:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/52/36681/abstract/71\">",
"      Westland C, Delaney W 4th, Yang H, et al. Hepatitis B virus genotypes and virologic response in 694 patients in phase III studies of adefovir dipivoxil1. Gastroenterology 2003; 125:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/52/36681/abstract/72\">",
"      Carman WF, Jacyna MR, Hadziyannis S, et al. Mutation preventing formation of hepatitis B e antigen in patients with chronic hepatitis B infection. Lancet 1989; 2:588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/52/36681/abstract/73\">",
"      Akahane Y, Yamanaka T, Suzuki H, et al. Chronic active hepatitis with hepatitis B virus DNA and antibody against e antigen in the serum. Disturbed synthesis and secretion of e antigen from hepatocytes due to a point mutation in the precore region. Gastroenterology 1990; 99:1113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/52/36681/abstract/74\">",
"      Brunetto MR, Giarin MM, Oliveri F, et al. Wild-type and e antigen-minus hepatitis B viruses and course of chronic hepatitis. Proc Natl Acad Sci U S A 1991; 88:4186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/52/36681/abstract/75\">",
"      Junker-Niepmann M, Bartenschlager R, Schaller H. A short cis-acting sequence is required for hepatitis B virus pregenome encapsidation and sufficient for packaging of foreign RNA. EMBO J 1990; 9:3389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/52/36681/abstract/76\">",
"      Lok AS, Akarca U, Greene S. Mutations in the pre-core region of hepatitis B virus serve to enhance the stability of the secondary structure of the pre-genome encapsidation signal. Proc Natl Acad Sci U S A 1994; 91:4077.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/52/36681/abstract/77\">",
"      Li JS, Tong SP, Wen YM, et al. Hepatitis B virus genotype A rarely circulates as an HBe-minus mutant: possible contribution of a single nucleotide in the precore region. J Virol 1993; 67:5402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/52/36681/abstract/78\">",
"      Rodriguez-Frias F, Buti M, Jardi R, et al. Hepatitis B virus infection: precore mutants and its relation to viral genotypes and core mutations. Hepatology 1995; 22:1641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/52/36681/abstract/79\">",
"      Watanabe K, Takahashi T, Takahashi S, et al. Comparative study of genotype B and C hepatitis B virus-induced chronic hepatitis in relation to the basic core promoter and precore mutations. J Gastroenterol Hepatol 2005; 20:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/52/36681/abstract/80\">",
"      Yuh CH, Chang YL, Ting LP. Transcriptional regulation of precore and pregenomic RNAs of hepatitis B virus. J Virol 1992; 66:4073.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/52/36681/abstract/81\">",
"      Buckwold VE, Xu Z, Chen M, et al. Effects of a naturally occurring mutation in the hepatitis B virus basal core promoter on precore gene expression and viral replication. J Virol 1996; 70:5845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/52/36681/abstract/82\">",
"      Scaglioni PP, Melegari M, Wands JR. Biologic properties of hepatitis B viral genomes with mutations in the precore promoter and precore open reading frame. Virology 1997; 233:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/52/36681/abstract/83\">",
"      Okamoto H, Tsuda F, Akahane Y, et al. Hepatitis B virus with mutations in the core promoter for an e antigen-negative phenotype in carriers with antibody to e antigen. J Virol 1994; 68:8102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/52/36681/abstract/84\">",
"      Takahashi K, Aoyama K, Ohno N, et al. The precore/core promoter mutant (T1762A1764) of hepatitis B virus: clinical significance and an easy method for detection. J Gen Virol 1995; 76 ( Pt 12):3159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/52/36681/abstract/85\">",
"      Kurosaki M, Enomoto N, Asahina Y, et al. Mutations in the core promoter region of hepatitis B virus in patients with chronic hepatitis B. J Med Virol 1996; 49:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/52/36681/abstract/86\">",
"      Kidd-Ljunggren K, Oberg M, Kidd AH. Hepatitis B virus X gene 1751 to 1764 mutations: implications for HBeAg status and disease. J Gen Virol 1997; 78 ( Pt 6):1469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/52/36681/abstract/87\">",
"      Moriyama K, Okamoto H, Tsuda F, Mayumi M. Reduced precore transcription and enhanced core-pregenome transcription of hepatitis B virus DNA after replacement of the precore-core promoter with sequences associated with e antigen-seronegative persistent infections. Virology 1996; 226:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/52/36681/abstract/88\">",
"      Buckwold VE, Xu Z, Yen TS, Ou JH. Effects of a frequent double-nucleotide basal core promoter mutation and its putative single-nucleotide precursor mutations on hepatitis B virus gene expression and replication. J Gen Virol 1997; 78 ( Pt 8):2055.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/52/36681/abstract/89\">",
"      G&uuml;nther S, Piwon N, Will H. Wild-type levels of pregenomic RNA and replication but reduced pre-C RNA and e-antigen synthesis of hepatitis B virus with C(1653) --&gt; T, A(1762) --&gt; T and G(1764) --&gt; A mutations in the core promoter. J Gen Virol 1998; 79 ( Pt 2):375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/52/36681/abstract/90\">",
"      Sato S, Suzuki K, Akahane Y, et al. Hepatitis B virus strains with mutations in the core promoter in patients with fulminant hepatitis. Ann Intern Med 1995; 122:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/52/36681/abstract/91\">",
"      Kao JH, Chen PJ, Lai MY, Chen DS. Basal core promoter mutations of hepatitis B virus increase the risk of hepatocellular carcinoma in hepatitis B carriers. Gastroenterology 2003; 124:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/52/36681/abstract/92\">",
"      Fang ZL, Ling R, Wang SS, et al. HBV core promoter mutations prevail in patients with hepatocellular carcinoma from Guangxi, China. J Med Virol 1998; 56:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/52/36681/abstract/93\">",
"      Baptista M, Kramvis A, Kew MC. High prevalence of 1762(T) 1764(A) mutations in the basic core promoter of hepatitis B virus isolated from black Africans with hepatocellular carcinoma compared with asymptomatic carriers. Hepatology 1999; 29:946.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/52/36681/abstract/94\">",
"      Chan HL, Hussain M, Lok AS. Different hepatitis B virus genotypes are associated with different mutations in the core promoter and precore regions during hepatitis B e antigen seroconversion. Hepatology 1999; 29:976.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/52/36681/abstract/95\">",
"      Chan HL, Leung NW, Hussain M, et al. Hepatitis B e antigen-negative chronic hepatitis B in Hong Kong. Hepatology 2000; 31:763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/52/36681/abstract/96\">",
"      Kao JH, Wu NH, Chen PJ, et al. Hepatitis B genotypes and the response to interferon therapy. J Hepatol 2000; 33:998.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/52/36681/abstract/97\">",
"      Wai CT, Chu CJ, Hussain M, Lok AS. HBV genotype B is associated with better response to interferon therapy in HBeAg(+) chronic hepatitis than genotype C. Hepatology 2002; 36:1425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/52/36681/abstract/98\">",
"      Erhardt A, Blondin D, Hauck K, et al. Response to interferon alfa is hepatitis B virus genotype dependent: genotype A is more sensitive to interferon than genotype D. Gut 2005; 54:1009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/52/36681/abstract/99\">",
"      Janssen HL, van Zonneveld M, Senturk H, et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet 2005; 365:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/52/36681/abstract/100\">",
"      Flink HJ, van Zonneveld M, Hansen BE, et al. Treatment with Peg-interferon alpha-2b for HBeAg-positive chronic hepatitis B: HBsAg loss is associated with HBV genotype. Am J Gastroenterol 2006; 101:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/52/36681/abstract/101\">",
"      Buster EH, Flink HJ, Cakaloglu Y, et al. Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b. Gastroenterology 2008; 135:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/52/36681/abstract/102\">",
"      Lau GK, Piratvisuth T, Luo KX, et al. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005; 352:2682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/52/36681/abstract/103\">",
"      Bonino F, Marcellin P, Lau GK, et al. Predicting response to peginterferon alpha-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B. Gut 2007; 56:699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/52/36681/abstract/104\">",
"      Kao JH, Liu CJ, Chen DS. Hepatitis B viral genotypes and lamivudine resistance. J Hepatol 2002; 36:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/52/36681/abstract/105\">",
"      Yuen MF, Wong DK, Sablon E, et al. Hepatitis B virus genotypes B and C do not affect the antiviral response to lamivudine. Antivir Ther 2003; 8:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/52/36681/abstract/106\">",
"      Akuta N, Suzuki F, Kobayashi M, et al. The influence of hepatitis B virus genotype on the development of lamivudine resistance during long-term treatment. J Hepatol 2003; 38:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/52/36681/abstract/107\">",
"      Yuen MF, Yuan HJ, Sablon E, et al. Long-term follow-up study of Chinese patients with YMDD mutations: significance of hepatitis B virus genotypes and characteristics of biochemical flares. J Clin Microbiol 2004; 42:3932.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/52/36681/abstract/108\">",
"      Chien RN, Yeh CT, Tsai SL, et al. Determinants for sustained HBeAg response to lamivudine therapy. Hepatology 2003; 38:1267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/52/36681/abstract/109\">",
"      Fung SK, Wong F, Hussain M, Lok AS. Sustained response after a 2-year course of lamivudine treatment of hepatitis B e antigen-negative chronic hepatitis B. J Viral Hepat 2004; 11:432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/52/36681/abstract/110\">",
"      Z&ouml;llner B, Petersen J, Schr&ouml;ter M, et al. 20-fold increase in risk of lamivudine resistance in hepatitis B virus subtype adw. Lancet 2001; 357:934.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/52/36681/abstract/111\">",
"      Buti M, Cotrina M, Valdes A, et al. Is hepatitis B virus subtype testing useful in predicting virological response and resistance to lamivudine? J Hepatol 2002; 36:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/52/36681/abstract/112\">",
"      Z&ouml;llner B, Petersen J, Puchhammer-St&ouml;ckl E, et al. Viral features of lamivudine resistant hepatitis B genotypes A and D. Hepatology 2004; 39:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/52/36681/abstract/113\">",
"      Thakur V, Sarin SK, Rehman S, et al. Role of HBV genotype in predicting response to lamivudine therapy in patients with chronic hepatitis B. Indian J Gastroenterol 2005; 24:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/52/36681/abstract/114\">",
"      Fung SK, Chae HB, Fontana RJ, et al. Virologic response and resistance to adefovir in patients with chronic hepatitis B. J Hepatol 2006; 44:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/52/36681/abstract/115\">",
"      Sherman M, Yurdaydin C, Simsek H, et al. Entecavir therapy for lamivudine-refractory chronic hepatitis B: improved virologic, biochemical, and serology outcomes through 96 weeks. Hepatology 2008; 48:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/52/36681/abstract/116\">",
"      Zeuzem S, Gane E, Liaw YF, et al. Baseline characteristics and early on-treatment response predict the outcomes of 2 years of telbivudine treatment of chronic hepatitis B. J Hepatol 2009; 51:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/52/36681/abstract/117\">",
"      Devarbhavi HC, Cohen AJ, Patel R, et al. Preliminary results: outcome of liver transplantation for hepatitis B virus varies by hepatitis B virus genotype. Liver Transpl 2002; 8:550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/52/36681/abstract/118\">",
"      Girlanda R, Mohsen AH, Smith H, et al. Hepatitis B virus genotype A and D and clinical outcomes of liver transplantation for HBV-related disease. Liver Transpl 2004; 10:58.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3644 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-200.131.240.2-6FA69E1D15-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_52_36681=[""].join("\n");
var outline_f35_52_36681=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H19\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      SUBGROUPS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      RECOMBINATION AND COINFECTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      RELATIONSHIP OF GENOTYPES TO SEROTYPES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      DETERMINATION OF GENOTYPES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      GENOTYPES/SEROTYPES-DISEASE PROGRESSION AND HBEAG SEROCONVERSION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Hepatocellular carcinoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Chronicity of infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Fulminant hepatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      SERUM QUANTITATIVE HBV DNA LEVELS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      PRECORE VARIANTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      CORE PROMOTER VARIANTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      RESPONSES TO INTERFERON",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      RESPONSES TO LAMIVUDINE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      RESPONSE TO ADEFOVIR DIPIVOXIL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      RESPONSE TO ENTECAVIR OR TELBIVUDINE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      RECURRENCE AFTER TRANSPLANTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/3644\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/3644|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?11/56/12161\" title=\"figure 1\">",
"      HBV genotype distribution",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/3644|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?12/28/12747\" title=\"table 1\">",
"      Correlation HBV serotyp genotyp",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?3/15/3324\" title=\"table 2\">",
"      Diff HBV genotypes B and C",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/35/21045?source=related_link\">",
"      Characteristics of the hepatitis B virus and pathogenesis of infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/60/14281?source=related_link\">",
"      Standard and pegylated interferon for chronic hepatitis B virus infection",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_52_36682="Treatment of the mixed cryoglobulinemia syndrome";
var content_f35_52_36682=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of the mixed cryoglobulinemia syndrome",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/52/36682/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/52/36682/contributors\">",
"     Fernando C Fervenza, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/52/36682/contributors\">",
"     Michael D Leise, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/52/36682/contributors\">",
"     Dario Roccatello, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/52/36682/contributors\">",
"     Robert A Kyle, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/52/36682/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/52/36682/contributors\">",
"     Richard J Glassock, MD, MACP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/52/36682/contributors\">",
"     Mark H Wener, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/52/36682/contributors\">",
"     Deputy Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/52/36682/contributors\">",
"     John P Forman, MD, MSc",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/52/36682/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?35/52/36682/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 5, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mixed cryoglobulinemia syndrome is most often induced by hepatitis C virus (HCV) infection. It can also be associated with autoimmune or lymphoproliferative disorders or, rarely, can be idiopathic. Typically, it follows a chronic, smoldering course. Infrequently, mixed cryoglobulinemia may present with a rapidly progressive or even life-threatening course. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/63/22522?source=see_link\">",
"     \"Overview of cryoglobulins and cryoglobulinemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/15/34040?source=see_link\">",
"     \"Clinical manifestations and diagnosis of the mixed cryoglobulinemia syndrome (essential mixed cryoglobulinemia)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The main indication for immunosuppressive therapy is progressive systemic disease affecting the kidneys, nervous system, gastrointestinal tract, skin, or digits. The prognosis is variable [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/52/36682/abstract/1-5\">",
"     1-5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The treatment of patients with the mixed cryoglobulinemia syndrome will be reviewed here. An overview of cryoglobulinemia and a discussion of the clinical manifestations and diagnosis of the mixed cryoglobulinemia syndrome are provided elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/63/22522?source=see_link\">",
"     \"Overview of cryoglobulins and cryoglobulinemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/15/34040?source=see_link\">",
"     \"Clinical manifestations and diagnosis of the mixed cryoglobulinemia syndrome (essential mixed cryoglobulinemia)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GENERAL APPROACH TO THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prior to the discovery of the association with hepatitis C virus (HCV), both",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    and cytotoxic drugs (such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/52/35654?source=see_link\">",
"     chlorambucil",
"    </a>",
"    ) were often used in patients with mixed cryoglobulinemia. However, except in those patients with a rapidly progressive course, there was no clear evidence that these modalities were beneficial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/52/36682/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     Rituximab",
"    </a>",
"    has been gradually replacing cytotoxic drug therapy in such patients.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     Rituximab",
"    </a>",
"    is significantly more expensive than",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    , and there are no data directly comparing rituximab with cyclophosphamide in these patients. Thus, cyclophosphamide should still be considered a therapeutic option in patients with mixed cryoglobulinemia, especially in life-threatening situations.",
"   </p>",
"   <p>",
"    The general approach to therapy in patients with mixed cryoglobulinemia syndrome includes two broad principles:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Initial immunosuppressive therapy &ndash; Immunosuppression is provided as initial therapy in those patients identified as having a rapidly progressive, organ-threatening, or life-threatening course, regardless of the etiology of the mixed cryoglobulinemia. Immunosuppressive therapy usually combines a short course of glucocorticoids with either",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      and, in some patients, plasmapheresis. (See",
"      <a class=\"local\" href=\"#H17909481\">",
"       'Immunosuppressive therapy for severe mixed cryoglobulinemia'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Treatment of the underlying disease &ndash; All patients should receive therapy directed against the underlying etiology of the mixed cryoglobulinemia. As examples, patients with HCV who have chronic active hepatitis should receive antiviral therapy, while patients with an underlying lymphoproliferative disorder should receive appropriate disease-specific therapy. In some cases, this will involve continuation of immunosuppression for a prolonged period. (See",
"      <a class=\"local\" href=\"#H17909507\">",
"       'Treat the underlying disorder in all patients'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17909481\">",
"    <span class=\"h1\">",
"     IMMUNOSUPPRESSIVE THERAPY FOR SEVERE MIXED CRYOGLOBULINEMIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with mixed cryoglobulinemia who have a rapidly progressive, organ-threatening, or life-threatening course should receive immunosuppressive therapy including",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    or, if unavailable,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/52/36682/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. After disease stabilization, patients should receive concurrent therapy for the underlying disorder responsible for the cryoglobulinemia (eg, antiviral therapy in patients with active hepatitis C virus [HCV] infection). Exceptions to this general principle include mixed cryoglobulinemia due to HIV or HBV infections; in such patients, antiviral therapy should always be initiated before or at the same time as immunosuppressive therapy. (See",
"    <a class=\"local\" href=\"#H17909507\">",
"     'Treat the underlying disorder in all patients'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17909544\">",
"    <span class=\"h2\">",
"     Patient selection",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with mixed cryoglobulinemia syndrome who have one or more of the following manifestations, we suggest immunosuppressive therapy to rapidly improve or resolve target organ damage, rather than therapy directed at the underlying etiology alone:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Glomerulonephritis associated with either a rapidly progressive course",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      nephrotic range proteinuria",
"     </li>",
"     <li>",
"      Severe digital ischemia threatening amputation",
"     </li>",
"     <li>",
"      Gastrointestinal vasculitis associated with abdominal pain",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      gastrointestinal bleeding",
"     </li>",
"     <li>",
"      Rapidly progressive neuropathy",
"     </li>",
"     <li>",
"      Central nervous system vasculitis that may present as a stroke or acute cognitive impairment",
"     </li>",
"     <li>",
"      Pulmonary vasculitis associated with diffuse alveolar hemorrhage or respiratory failure",
"     </li>",
"     <li>",
"      Heart failure",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As discussed below in detail, we usually initiate immunosuppressive therapy in patients with HCV-associated mixed cryoglobulinemia",
"    <strong>",
"     prior",
"    </strong>",
"    to instituting antiviral treatment. (See",
"    <a class=\"local\" href=\"#H1233455\">",
"     'Initiation of HCV therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Support for immunosuppressive therapy in patients with severe manifestations comes from randomized trials and observational data in which",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    was combined with disease-specific therapy (usually antiviral therapy in patients with HCV infection). The following examples illustrate the most relevant findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a randomized trial, 59 patients with mixed cryoglobulinemia and severe manifestations were assigned to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      therapy or other immunosuppressive agents; in the 53 patients whose disease was due to HCV infection, antiviral therapy had either failed or was not indicated [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/52/36682/abstract/8\">",
"       8",
"      </a>",
"      ]. Clinical improvement was noted at 12 and 24 months in greater than 60 percent of patients receiving rituximab. These data provide the strongest evidence that immunosuppressive therapy is effective in patients with severe disease, including those with HCV-associated cryoglobulinemia. The comparative effects of rituximab versus other immunosuppressive drugs are presented below. (See",
"      <a class=\"local\" href=\"#H571919\">",
"       'Preference for rituximab'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      In a prospective cohort study of 93 patients with HCV-associated mixed cryoglobulinemia, 55 received antiviral therapy with pegylated interferon and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"       ribavirin",
"      </a>",
"      alone, and 38 received",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      (375",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      given weekly for one month [4 doses]) followed one month later by pegylated interferon and ribavirin; median follow-up was 48 months [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/52/36682/abstract/9\">",
"       9",
"      </a>",
"      ]. At baseline, 81 percent of patients had neurological involvement, 33 percent had kidney involvement, and 9 percent had gastrointestinal involvement. Compared with patients who received antiviral therapy alone, patients who received combined therapy with antiviral drugs plus rituximab were more likely to have severe manifestations at baseline, including renal involvement (55 versus 18 percent [estimated glomerular filtration rate, 43 versus 59",
"      <span class=\"nowrap\">",
"       mL/min/1.73m",
"       <sup>",
"        2",
"       </sup>",
"       ]).",
"      </span>",
"      The rate of a complete clinical response (defined as an improvement in all baseline clinical features) was similar in patients receiving combination therapy as compared with antiviral therapy alone (74 versus 73 percent), but the time until clinical response was significantly shorter with combination therapy (5.4 versus 8.4 months). In addition, combination therapy was associated with a significantly larger improvement in glomerular filtration rate (GFR), a significantly larger decline in proteinuria, and a significantly greater likelihood of achieving a complete renal response (81 versus 40 percent). The relapse rate was similar among the treatment groups.",
"     </li>",
"     <li>",
"      A retrospective study evaluated the response to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      in 87 patients with mixed cryoglobulinemia (80 [92 percent] of whom had HCV infection) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/52/36682/abstract/10\">",
"       10",
"      </a>",
"      ]. Approximately half of the patients had previously received antiviral therapy. Rituximab was given for the following indications: glomerulonephritis (30 percent), peripheral neuropathy (23 percent), severe cutaneous vasculitis (25 percent), and multiple manifestations (14 percent). The dose of rituximab varied, with 68 percent receiving four weekly infusions (375",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"       )",
"      </span>",
"      and 21 percent receiving two doses of 1000 mg separated by a two-week interval. At six months, a complete resolution of peripheral neuropathy occurred in 44 percent of patients, and complete healing of cutaneous ulcers occurred in 87 percent of patients. Glomerulonephritis improved in 95 percent of patients, with complete remission in 50 percent marked by normalization of serum creatinine and proteinuria.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The downstream autoimmune effects of HCV infection provide biological rationale for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    therapy in patients whose disease is triggered by HCV infection. Specifically, chronic HCV infection is associated with polyclonal or oligoclonal B lymphocyte expansion that can result in the production of autoreactive antibodies. This autoimmune process can persist and produce disease manifestations even after effective antiviral therapy and complete suppression of viremia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/52/36682/abstract/11,12\">",
"     11,12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The magnitude of the benefit from aggressive therapy in patients with severe disease is related to the phase of illness. As an example, if polyneuropathy is already advanced when therapy is initiated, the benefit is less impressive [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/52/36682/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     Rituximab",
"    </a>",
"    also appears to provide effective therapy in patients with the mixed cryoglobulinemia syndrome not associated with chronic HCV infection. In the French multicenter CryoVas survey, for example, 242 patients were identified who were HCV, HBV, and HIV negative and who had mixed cryoglobulinemia and vasculitis; 30 percent had an underlying rheumatologic disorder, 22 percent had a lymphoproliferative disorder, and the remainder had idiopathic (essential) mixed cryoglobulinemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/52/36682/abstract/14\">",
"     14",
"    </a>",
"    ]. In adjusted analyses, combination therapy with rituximab and glucocorticoids was associated with a nearly fourfold higher rate of achieving a complete clinical response as compared with glucocorticoid therapy alone. In contrast, the combination of alkylating agents (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    ) with glucocorticoids was not significantly associated with a better clinical response than glucocorticoids alone. However, severe infections were more common with rituximab, and mortality was similar regardless of the treatment used.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17909552\">",
"    <span class=\"h2\">",
"     Choice of immunosuppressive therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In most patients selected for initial immunosuppressive therapy, we suggest",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    rather than other immunosuppressive drugs such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    or glucocorticoids alone. In addition, we suggest pulse glucocorticoid therapy followed by a rapid taper in most patients rather than prolonged glucocorticoid therapy or no glucocorticoid therapy. In those patients with life-threatening disease or cryoglobulinemia-associated hyperviscosity syndrome, we also suggest plasmapheresis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/12/12484?source=see_link\">",
"     \"Plasma exchange in the hyperviscosity syndrome due to immunoglobulins\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The rationale for these suggestions and the regimens used are discussed below. (See",
"    <a class=\"local\" href=\"#H571927\">",
"     'Rituximab regimen'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H1233191\">",
"     'Glucocorticoid regimen'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    However, there are settings in which we would",
"    <strong>",
"     not",
"    </strong>",
"    use",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    to treat mixed cryoglobulinemia:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients with HIV infection who are not receiving highly active antiretroviral therapy (HAART) or if, in those patients receiving HAART, the viral load is not suppressed. Such patients are at high risk for enhanced viral replication as a result of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      therapy. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?35/24/36234?source=see_link\">",
"       \"Selecting antiretroviral regimens for the treatment naive HIV-infected patient\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In patients with HBV infection who are not receiving antiviral therapy or have chronic active hepatitis. The preferred antiviral regimens are discussed below. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Anti-HBV therapy'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These suggestions for immunosuppressive therapy, particularly the suggestion that glucocorticoids be tapered rapidly, apply to most treated patients since the great majority of such patients will have mixed cryoglobulinemia syndrome due to a chronic viral infection (mainly HCV infection). However, some patients may require alternate immunosuppressive regimens tailored to treat the underlying cause, such as autoimmune diseases (eg, rheumatoid arthritis) and lymphoproliferative disorders. This is discussed below. (See",
"    <a class=\"local\" href=\"#H6575895\">",
"     'Autoimmune disorders'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H6575986\">",
"     'Lymphoma'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H571879\">",
"     'Idiopathic disease'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H571919\">",
"    <span class=\"h3\">",
"     Preference for rituximab",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two open-label randomized trials suggest that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    is effective in patients with severe mixed cryoglobulinemia:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A multicenter trial assigned 59 patients with mixed cryoglobulinemia (93 percent with HCV infection) and severe manifestations (defined as the presence of skin ulcerations, active glomerulonephritis, or progressive peripheral neuropathy) to either",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      therapy (1000 mg intravenous infusion at baseline and at day 14) or conventional immunosuppressive therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/52/36682/abstract/8\">",
"       8",
"      </a>",
"      ]. Conventional immunosuppressive therapy varied according to the treating physician; of 29 patients assigned to conventional therapy, 17 received glucocorticoids alone, 5 received plasmapheresis, 4 received",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      , and 3 received",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      . The primary endpoint was success of the initial therapy through 12 months; failure of treatment was due either to a lack of clinical improvement or side effects requiring that the therapy be altered. Significantly more patients receiving rituximab therapy had treatment success at 12 months (64 versus 4 percent) and at 24 months (61 versus 4 percent). Of those patients initially receiving conventional therapy who had a treatment failure, 60 percent had a favorable response to rituximab.",
"     </li>",
"     <li>",
"      A single-center trial assigned 24 patients with mixed cryoglobulinemia due to HCV infection to receive either",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      therapy (375",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      given weekly for one month [4 doses]) or to continue their current treatments [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/52/36682/abstract/15\">",
"       15",
"      </a>",
"      ]. At baseline, 33 percent had active glomerulonephritis, 50 percent had peripheral neuropathy, and 25 percent had cutaneous ulcers. All patients had either failed to achieve a clinical response with antiviral therapy alone or failed to tolerate antiviral therapy. Of the twelve patients assigned to rituximab therapy, six also received glucocorticoids (mean dose 26 mg",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      per day), one also received",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      , and two also received plasmapheresis. Of the twelve patients assigned to continue their current treatment, three received glucocorticoids (mean dose 10 mg prednisone per day). At six months, significantly more patients in the rituximab group achieved clinical remission (10 of 12 versus 1 of 12), which was defined as a Birmingham Vasculitis Activity Score equal to zero.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These trials showed that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    therapy was effective in patients with mixed cryoglobulinemia and severe manifestations, allowed for reductions in glucocorticoid use, and did not lead to a worsening of hepatitis. However, neither demonstrated that rituximab was superior to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    therapy or plasmapheresis. In the first trial, most patients in the control group were receiving glucocorticoid therapy alone (at a mean",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    dose of 28",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/52/36682/abstract/8\">",
"     8",
"    </a>",
"    ]; in the second trial, most patients in the control group received no immunosuppressive therapy, and those who did were treated with prednisone at a low dose [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/52/36682/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The efficacy of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    in patients with mixed cryoglobulinemia has also been shown in numerous observational studies and case series [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/52/36682/abstract/13,16-20\">",
"     13,16-20",
"    </a>",
"    ]. The following examples illustrate the range of findings in various patient subgroups:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with cirrhosis &ndash; Most studies of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      have excluded patients with cirrhosis or have included very small numbers of cirrhotics. In a prospective study, 15 patients with mixed cryoglobulinemia and cirrhosis due to HCV infection were treated with rituximab (375",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"       ,",
"      </span>",
"      weekly for four weeks) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/52/36682/abstract/19\">",
"       19",
"      </a>",
"      ]. The majority of patients had a complete, major, or partial response to rituximab with respect to ulcers, purpura, neuropathic pain, nephritis, or arthralgias. Most patients also had an improvement in the Child-Pugh score, an increase in serum albumin, and a decreased requirement for albumin infusions and diuretics. Of the six patients with ascites, all had an impressive reduction or disappearance of ascites. However, this unblinded study should be interpreted with caution since the diagnosis of ascites and the Child-Pugh score can be subjective. In addition, a full discussion of adverse events was not included. Although these are encouraging, further studies of rituximab in patients with cirrhosis are required before it is used widely in such patients. Thus, the presence of decompensated cirrhosis is a relative contraindication to rituximab therapy.",
"     </li>",
"     <li>",
"      Patients with glomerulonephritis &ndash; Among 11 patients from two series with mixed cryoglobulinemia and biopsy-proven glomerulonephritis due to HCV infection, intravenous",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      alone (375",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      weekly [four doses] initially followed by two additional doses at months 2 and 3) was associated with improvements in serum creatinine",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      proteinuria in all patients, paralleled by an increase in complement factor 4 (C4) levels [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/52/36682/abstract/16,17\">",
"       16,17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Patients with severe polyneuropathy &ndash; Thirteen patients with mixed cryoglobulinemia and polyneuropathy refractory to antiviral therapy and conventional immunosuppressive medications received",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      (375",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      weekly [four doses] initially followed by two additional doses at months 2 and 3) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/52/36682/abstract/13\">",
"       13",
"      </a>",
"      ]. Sensory symptoms disappeared or improved, while electromyography examination revealed that the amplitude of compound motor action potential had increased following treatment.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     Rituximab",
"    </a>",
"    was generally well-tolerated in these studies. Short-term infusion reactions following rituximab do not appear to be more frequent in mixed cryoglobulinemia than in rheumatoid arthritis. Severe adverse effects are uncommon, and drop-out due to adverse events, such as bradycardia (especially in older adults), is less than five percent. Special care should be taken for the prevention (eg, prophylaxis against Pneumocystis, administration of age-appropriate immunizations) and management of infections in patients who have previously been treated with immunosuppressants, especially immunocompromised renal transplant recipients with graft dysfunction due to mixed cryoglobulinemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/52/36682/abstract/21\">",
"     21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/4/9289?source=see_link\">",
"     \"Treatment and prevention of Pneumocystis pneumonia in non-HIV-infected patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/47/29433?source=see_link\">",
"     \"Infection in the solid organ transplant recipient\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H571927\">",
"    <span class=\"h3\">",
"     Rituximab regimen",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients selected for immunosuppressive therapy with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    , we use one of the following three regimens (each is acceptable):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Four infusions of 375",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      at weekly intervals (day 0, day 7, day 14, day 21)",
"     </li>",
"     <li>",
"      Two infusions of 1000 mg separated by a two-week interval (day 0 and day 14)",
"     </li>",
"     <li>",
"      Four infusions of 375",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      at weekly intervals (day 0, day 7, day 14, day 21) followed by additional doses at day 49 and day 77",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Infusing",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    slowly (ie, over 6 to 8 hours) or administration of half of the dose on two consecutive days, together with premedication using glucocorticoids,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    , and antihistamine drugs, reduces the risk of infusion reactions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/52/36682/abstract/10,13,17\">",
"     10,13,17",
"    </a>",
"    ]. Thus, to prevent infusion reactions, we premedicate with intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    (100 mg), oral acetaminophen (1000 mg), and oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/2/33824?source=see_link\">",
"     diphenhydramine",
"    </a>",
"    (50 mg) prior to each infusion.",
"   </p>",
"   <p>",
"    Lower doses of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    have been attempted in patients with mixed cryoglobulinemia, although they may be less effective. As an example, a study of 27 patients with HCV infection who either did not respond to or could not tolerate antiviral therapy were treated with rituximab, 250",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    followed by a second identical dose two weeks later [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/52/36682/abstract/22\">",
"     22",
"    </a>",
"    ]. Although 19 of 24 patients (79 percent) who were evaluated at three months had a complete or partial response, only 3 of 19 patients evaluated at twelve months were in remission. Thirteen patients were lost to follow-up due to relapse or lack of response. Thus, response rates with low-dose rituximab appear to be inferior to conventional dosing, although the two dosing strategies have not been directly compared.",
"   </p>",
"   <p>",
"    All patients who will receive",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    therapy should",
"    <strong>",
"     first be screened for hepatitis B virus",
"    </strong>",
"    infection by measuring hepatitis B surface antigen (HBsAg) and antibodies against the total core antigen (Anti-HBc). Rituximab can induce a severe and potentially fatal reactivation of hepatitis B virus. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/25/26009?source=see_link\">",
"     \"Hepatitis B virus reactivation associated with immunosuppression\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H543716\">",
"    <span class=\"h3\">",
"     Preference for a rapid glucocorticoid taper",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infections are a common serious complication of patients receiving immunosuppressive treatment for mixed cryoglobulinemia, and therefore long courses of high-dose steroids in conjunction with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    are not recommended [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/52/36682/abstract/23\">",
"     23",
"    </a>",
"    ]. A rapid taper is desired. However, in patients who do not respond completely or who experience significant disease recurrence when glucocorticoids are tapered, more prolonged courses of glucocorticoids or slower tapers may be required.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1233191\">",
"    <span class=\"h3\">",
"     Glucocorticoid regimen",
"    </span>",
"    &nbsp;&mdash;&nbsp;For severe presentations of the mixed cryoglobulinemia syndrome, we use initially high doses of glucocorticoids with the goal of rapidly tapering the dose. The following is an example of a regimen used by the authors and reviewers of this topic, although (as will be discussed) the specific management must be tailored to the individual:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Intravenous",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?30/25/31129?source=see_link\">",
"       methylprednisolone",
"      </a>",
"      , 7.5 to 15",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day, is given for three days based upon the severity of the illness. This is followed by oral",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      , 1",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day (maximum dose, 80",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      for two to four weeks, then 40",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      for two weeks, and then 20",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      for another two to four weeks. The dose is then tapered by 5 mg per week, aiming to discontinue therapy if tolerated. If patients are not also treated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      , then a maintenance dose of 5 to 10",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      is maintained.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The ability to taper glucocorticoids depends in part upon whether the patient responds to therapy. The clinical response to immunosuppressive therapy should be judged based upon resolution of the initial signs and symptoms (eg, improvement of renal function and proteinuria, healing of ulcers, etc) and not upon the concentration of the cryoglobulin (cryocrit). The cryoglobulin concentration does not correlate with either the clinical severity of disease or with the response to therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/52/36682/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In patients with viral-induced cryoglobulinemia, glucocorticoid therapy may need to be tapered more rapidly than desired if viral reactivation occurs. This is particularly true when mixed cryoglobulinemia is associated with HBV infections since glucocorticoid therapy can lead to viral reactivation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/25/26009?source=see_link&amp;anchor=H9#H9\">",
"     \"Hepatitis B virus reactivation associated with immunosuppression\", section on 'Glucocorticoids'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Role of plasma exchange",
"    </span>",
"    &nbsp;&mdash;&nbsp;We rarely use plasma exchange in patients with mixed cryoglobulinemia. However, there are several settings in which plasma exchange may be used [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/52/36682/abstract/6\">",
"     6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients with symptomatic hyperviscosity syndrome due to mixed cryoglobulinemia, we suggest that plasma exchange be used in combination with other therapy to reduce the production of cryoglobulins (such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?12/12/12484?source=see_link\">",
"       \"Plasma exchange in the hyperviscosity syndrome due to immunoglobulins\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In patients with life-threatening cryoglobulinemia (including patients with acute respiratory failure and pulmonary hemorrhage or acute intestinal vasculitis due to cryoglobulinemia), we suggest that plasma exchange be used in combination with other therapy to reduce the production of cryoglobulins [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/52/36682/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In patients with rapidly progressive (crescentic) glomerulonephritis who require dialysis, we suggest that plasma exchange be used (in combination with other therapy such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      ) to reduce the production of cryoglobulins. Late initiation of plasma exchange (ie, two or more weeks after the initiation of dialysis) is unlikely to be beneficial.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The evidence in support of plasma exchange comes mostly from small case reports and case series that suggest clinical improvement in patients with severe disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/52/36682/abstract/3,4,13,26-30\">",
"     3,4,13,26-30",
"    </a>",
"    ]. Support for plasma exchange is also based upon mechanistic grounds since plasma exchange removes circulating cryoglobulins. However, the concentration of the cryoglobulin (often measured as a cryocrit) does not correlate with clinical severity nor with response to therapy; thus, the decision to initiate this aggressive therapy is based upon the severity of the disease manifestations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/52/36682/abstract/24\">",
"     24",
"    </a>",
"    ]. Because plasma exchange does not prevent the formation of new cryoglobulins, it should be combined with other therapy (such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    ) directed at B cell clones that produce cryoglobulins [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/52/36682/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Plasma exchange prescription",
"    </span>",
"    &nbsp;&mdash;&nbsp;When initiated, we recommend daily plasma exchange for 10 to 14 sessions or three exchanges per week (eg, Monday, Wednesday, Friday) for two to three weeks. One plasma volume (approximately 3 liters) should be exchanged per session. The replacement fluid can be 5 percent albumin, which",
"    <strong>",
"     should be warmed",
"    </strong>",
"    to prevent precipitation of circulating cryoglobulins [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/52/36682/abstract/31\">",
"     31",
"    </a>",
"    ]. However, in patients who have undergone a recent kidney biopsy, fresh frozen plasma should be used as the replacement fluid rather than albumin in order to avoid severe bleeding. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/33/38420?source=see_link\">",
"     \"Prescription and technique of therapeutic plasma exchange\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The optimal method for assessing the efficacy of plasma exchange is uncertain. Changes in the percent cryocrit after plasmapheresis do not correlate closely with clinical activity. Clinical evaluation therefore assumes primary importance. Successful plasma exchange should lead to rapid resolution of purpuric lesions and, in a patient with acute kidney injury, a return toward the baseline serum creatinine concentration. In comparison, signs of neuropathy are not likely to remit during short-term therapy.",
"   </p>",
"   <p>",
"    When used, plasma exchange should be combined with therapy to prevent the production of new cryoglobulins such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/52/36682/abstract/25\">",
"     25",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H17909552\">",
"     'Choice of immunosuppressive therapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1230577\">",
"    <span class=\"h2\">",
"     Role of cyclophosphamide",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    therapy in patients with mixed cryoglobulinemia, particularly in patients with HCV or HBV infection, carries the risk of enhancing viral replication. In patients with organ-threatening or life-threatening disease, cyclophosphamide therapy may be used if",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    therapy is unavailable, fails to produce a clinical response, or is not tolerated. When used, cyclophosphamide is typically combined with plasma exchange [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/52/36682/abstract/4,32\">",
"     4,32",
"    </a>",
"    ]. The initial cyclophosphamide dose in such patients is 2",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day orally for two to four months. The dose should be adjusted according to the age and GFR. Dose adjustment is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/40/16008?source=see_link\">",
"     \"General principles of the use of cyclophosphamide in rheumatic and renal disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1576718960\">",
"    <span class=\"h2\">",
"     Antimicrobial prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of high-dose glucocorticoids in combination with either",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    carries a high risk for opportunistic infections, such as Pneumocystis pneumonia. Prophylaxis against such infections is mandatory in these patients. Patients should also receive age-appropriate immunizations, ideally several weeks before the initiation of immunosuppression. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/4/9289?source=see_link\">",
"     \"Treatment and prevention of Pneumocystis pneumonia in non-HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17909507\">",
"    <span class=\"h1\">",
"     TREAT THE UNDERLYING DISORDER IN ALL PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;All patients should receive therapy directed against the underlying etiology of the mixed cryoglobulinemia. As examples, patients with HCV and chronic active hepatitis should receive antiviral therapy, while patients with an underlying lymphoproliferative disorder should receive appropriate disease-specific therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Therapy for HCV infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;We agree with the recommendation from the European League Against Rheumatism (EULAR) and the Italian Group for the Study of Cryoglobulinemias (GISC) that patients with mixed cryoglobulinemia syndrome associated with HCV infection should be treated with antiviral therapy, with the exception of those patients with decompensated cirrhosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/52/36682/abstract/6,33\">",
"     6,33",
"    </a>",
"    ]. Immunosuppressive therapy should not be given without also attempting antiviral therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/52/36682/abstract/34-36\">",
"     34-36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This section will provide an overview of antiviral therapy for mixed cryoglobulinemia caused by HCV infection. The selection of patients for antiviral treatment, the general efficacy of these regimens in the treatment of chronic HCV, and the side effects associated with therapy are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/45/43735?source=see_link\">",
"     \"Overview of the management of chronic hepatitis C virus infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/33/28184?source=see_link\">",
"     \"Mechanism of action and efficacy of ribavirin for the treatment of chronic hepatitis C virus infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/23/41337?source=see_link\">",
"     \"Mechanism of action and efficacy of peginterferon for the treatment of chronic hepatitis C virus infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/9/16538?source=see_link\">",
"     \"Management of the side effects of peginterferon and ribavirin being used for treatment of chronic hepatitis C virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The selection of patients who should also receive immunosuppressive therapy and the suggested immunosuppressive regimens are discussed above. (See",
"    <a class=\"local\" href=\"#H17909481\">",
"     'Immunosuppressive therapy for severe mixed cryoglobulinemia'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1233414\">",
"    <span class=\"h3\">",
"     General approach to HCV therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Key questions related to antiviral therapy include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      When should antiviral therapy be initiated?",
"     </li>",
"     <li>",
"      What antiviral drug should be used and what is the dose?",
"     </li>",
"     <li>",
"      What is the duration of antiviral therapy?",
"     </li>",
"     <li>",
"      How should patients receiving antiviral therapy be monitored?",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In general, antiviral therapy should be delayed for one to four months in patients with severe disease who require initial therapy with immunosuppressant agents. (See",
"    <a class=\"local\" href=\"#H1233455\">",
"     'Initiation of HCV therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The specific antiviral drugs and doses used depend upon the HCV genotype (ie, interferon and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    for genotypes 2, 3, and 4, with the addition of either",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/40/27273?source=see_link\">",
"     boceprevir",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/6/20585?source=see_link\">",
"     telaprevir",
"    </a>",
"    for genotype 1) and also upon the renal function. (See",
"    <a class=\"local\" href=\"#H1233463\">",
"     'Drugs and dosing in HCV therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The duration of antiviral therapy is based upon the HCV genotype, prior treatment response, type of antiviral agent used, tolerance to treatment, and the clinical and laboratory response to treatment. In general, we favor 48 weeks of therapy in patients with genotype 1 or genotype 4, and 24 weeks in patients with genotype 2 and genotype 3. (See",
"    <a class=\"local\" href=\"#H546513\">",
"     'Duration of therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    We generally follow renal and hepatic function weekly during the first two weeks of antiviral therapy, and then monthly thereafter. HCV viral loads should be obtained at weeks 4, 12, 24, and 48, and then six months after the completion of therapy. The frequency of follow-up visits in the clinic depends upon the cryoglobulinemia disease activity, treatment regimen, comorbidities, and tolerance of therapy. (See",
"    <a class=\"local\" href=\"#H1233471\">",
"     'Monitoring of patients on antiviral therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1233455\">",
"    <span class=\"h3\">",
"     Initiation of HCV therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with chronic HCV infection (without decompensated cirrhosis) and mixed cryoglobulinemia, we recommend that antiviral therapy be attempted. However, among patients with severe vasculitic manifestations (eg, glomerulonephritis, cutaneous ulcers, progressive neuropathy) who have not yet been treated with antiviral therapy, we suggest that immunosuppressive therapy be initiated first and that antiviral therapy be delayed for one to four months. These recommendations and suggestions are in agreement with the EULAR and GISC guidelines [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/52/36682/abstract/6,9,33\">",
"     6,9,33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The rationale for delaying antiviral therapy by one to four months in patients who require immunosuppressive therapy is as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Immunosuppressive therapy can rapidly improve inflammation and resolve target organ damage. Clinical improvements due to antiviral therapy are gradual.",
"     </li>",
"     <li>",
"      High-dose immunosuppressive therapy and antiviral therapy each have side effects. Thus, patients may not be able to tolerate both treatments simultaneously.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Antiviral medications may occasionally produce renal, neurological, or cutaneous manifestations that could confound the evaluation of whether immunosuppressive therapy is effective.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1233463\">",
"    <span class=\"h3\">",
"     Drugs and dosing in HCV therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The antiviral drugs and doses used to treat chronic HCV infection in patients with mixed cryoglobulinemia follow the same general principles as they do in patients who do not have mixed cryoglobulinemia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/45/43735?source=see_link\">",
"     \"Overview of the management of chronic hepatitis C virus infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/47/24314?source=see_link\">",
"     \"Treatment regimens for chronic hepatitis C virus genotype 1\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/37/600?source=see_link\">",
"     \"Treatment regimens for chronic hepatitis C virus genotypes 2, 3, and 4\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Drug selection depends in part upon the HCV genotype:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Genotype 1 &ndash; Patients with HCV genotype 1 should receive pegylated interferon,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"       ribavirin",
"      </a>",
"      , and a protease inhibitor (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/6/20585?source=see_link\">",
"       telaprevir",
"      </a>",
"      or, preferably,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/40/27273?source=see_link\">",
"       boceprevir",
"      </a>",
"      ). As discussed later, however, patients with an estimated glomerular filtration rate (eGFR) less than 50",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73 m",
"      <sup>",
"       2",
"      </sup>",
"      should",
"      <strong>",
"       not",
"      </strong>",
"      receive a protease inhibitor.",
"     </li>",
"     <li>",
"      Genotype 2, 3, or 4 &ndash; Patients with infected HCV genotypes 2, 3, or 4 should receive pegylated interferon and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"       ribavirin",
"      </a>",
"      .",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Between the available protease inhibitors, we prefer",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/40/27273?source=see_link\">",
"     boceprevir",
"    </a>",
"    in patients with mixed cryoglobulinemia because",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/6/20585?source=see_link\">",
"     telaprevir",
"    </a>",
"    may cause a rash in up to 56 percent of patients. Although the rash associated with telaprevir is usually maculopapular (as opposed to purpuric), it could be confused with worsening cutaneous manifestations in patients with mixed cryoglobulinemia. Boceprevir is much less likely to cause a rash and might be favored in this circumstance. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/47/24314?source=see_link&amp;anchor=H148834010#H148834010\">",
"     \"Treatment regimens for chronic hepatitis C virus genotype 1\", section on 'Treatment regimens'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/47/24314?source=see_link&amp;anchor=H148836537#H148836537\">",
"     \"Treatment regimens for chronic hepatitis C virus genotype 1\", section on 'Telaprevir'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Drug selection also depends upon the baseline eGFR. This is an important consideration in patients with mixed cryoglobulinemia because 20 to 30 percent of affected patients will have renal manifestations. We suggest the following therapeutic approach based upon the 2011 FDA guidelines pertaining to the use of pegylated interferon alfa 2a and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    according to eGFR:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      eGFR greater than 50",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73 m",
"      <sup>",
"       2",
"      </sup>",
"      &ndash; Pegylated interferon and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"       ribavirin",
"      </a>",
"      are given at doses that are identical to those recommended for patients with chronic HCV infection who have normal renal function. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/47/24314?source=see_link&amp;anchor=H148833698#H148833698\">",
"       \"Treatment regimens for chronic hepatitis C virus genotype 1\", section on 'Doses of peginterferon and ribavirin'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?0/37/600?source=see_link&amp;anchor=H488644295#H488644295\">",
"       \"Treatment regimens for chronic hepatitis C virus genotypes 2, 3, and 4\", section on 'Doses of peginterferon and ribavirin'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      eGFR 30 to 50",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73 m",
"      <sup>",
"       2",
"      </sup>",
"      &ndash; Pegylated interferon alfa 2a is given subcutaneously at a dose of 180 mcg per week;",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"       ribavirin",
"      </a>",
"      is given orally at alternating doses of 200 and 400 mg every other day.",
"     </li>",
"     <li>",
"      eGFR 15 to 29",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73 m",
"      <sup>",
"       2",
"      </sup>",
"      &ndash; Pegylated interferon alfa 2a is given subcutaneously at a dose of 135 mcg per week;",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"       ribavirin",
"      </a>",
"      is given orally at a dose of 200 mg per day.",
"     </li>",
"     <li>",
"      eGFR &lt;15",
"      <span class=\"nowrap\">",
"       ml/min",
"      </span>",
"      or on dialysis (hemodialysis or peritoneal dialysis) &ndash; Treatment is controversial. We suggest one of the following: standard interferon alfa (2a or 2b), 3 million units three times weekly;",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/36/24137?source=see_link\">",
"       pegylated interferon alfa-2b",
"      </a>",
"      , 1",
"      <span class=\"nowrap\">",
"       mcg/kg",
"      </span>",
"      per week; or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/27/27064?source=see_link\">",
"       pegylated interferon alfa-2a",
"      </a>",
"      , 135 mcg per week plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"       ribavirin",
"      </a>",
"      at 200",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      with close monitoring.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The Cockcroft-Gault equation is used to calculate eGFR for the purposes of dosing antiviral therapy (",
"    <a class=\"calc calc_professional\" href=\"mobipreview.htm?29/57/30609?source=see_link\">",
"     calculator 1",
"    </a>",
"    and",
"    <a class=\"calc calc_professional\" href=\"mobipreview.htm?19/22/19809?source=see_link\">",
"     calculator 2",
"    </a>",
"    ). This equation is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/45/36570?source=see_link&amp;anchor=H20659776#H20659776\">",
"     \"Assessment of kidney function\", section on 'Cockcroft-Gault equation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/45/36570?source=see_link&amp;anchor=H20659832#H20659832\">",
"     \"Assessment of kidney function\", section on 'Drug dosing'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The patient's weight is used in the Cockcroft-Gault equation. However, the dosing body weight, rather than actual body weight, should be used. If the patient's actual body weight is not more than 20 percent above ideal body weight, then dosing weight is equal to ideal body weight. However, if the actual body weight is more than 20 percent above ideal body weight, then the dosing weight is somewhat higher. The following calculator permits calculation of ideal body weight and dosing weight (",
"    <a class=\"calc calc_professional\" href=\"mobipreview.htm?2/41/2706?source=see_link\">",
"     calculator 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The above approach for dosing in the setting of kidney disease differs slightly from published guidelines and is based upon personal experience. The American Association for the Study of Liver Disease (AASLD) recommended the following [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/52/36682/abstract/37\">",
"     37",
"    </a>",
"    ]: patients with an eGFR greater than 60",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m",
"    <sup>",
"     2",
"    </sup>",
"    should receive standard doses of pegylated interferon and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    that would be utilized in patients without kidney disease; patients with an eGFR less than 60",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m",
"    <sup>",
"     2",
"    </sup>",
"    who are not on dialysis should receive either pegylated interferon alfa 2a at a dose of 135 mcg per week or pegylated interferon alfa 2b at a dose of 1",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    per week and ribavirin at 200 to 800 mg per day with careful monitoring. The Kidney Disease Improving Global Outcomes (KDIGO) guidelines from 2008 provided different recommendations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/52/36682/abstract/38\">",
"     38",
"    </a>",
"    ]: patients with an eGFR greater than or equal to 50",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m",
"    <sup>",
"     2",
"    </sup>",
"    should receive standard pegylated interferon and ribavirin doses; patients with an eGFR greater than or equal to 15 but less 50",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m",
"    <sup>",
"     2",
"    </sup>",
"    should receive pegylated interferon monotherapy adjusted for level of kidney function and no ribavirin; patients with an eGFR less than 15",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m",
"    <sup>",
"     2",
"    </sup>",
"    should receive standard (non-pegylated) interferon with dose adjustments based upon the level of renal function.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/6/20585?source=see_link\">",
"     Telaprevir",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/40/27273?source=see_link\">",
"     boceprevir",
"    </a>",
"    are primarily metabolized by the liver and therefore should not require dose adjustments based upon glomerular filtration rate (GFR). However, these drugs have not been evaluated in patients with reduced kidney function. Thus, while awaiting additional safety and efficacy data, they should",
"    <strong>",
"     not",
"    </strong>",
"    be used in patients with an eGFR less than 50",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m",
"    <sup>",
"     2",
"    </sup>",
"    .",
"   </p>",
"   <p>",
"    It should be emphasized that a multidisciplinary approach is needed to best care for patients with HCV and mixed cryoglobulinemia. The multidisciplinary team should include a nephrologist, a hepatologist, and a rheumatologist who all have experience in treating these complex patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H407972\">",
"    <span class=\"h4\">",
"     Evidence for efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of cryoglobulinemia does not appear to dampen the response to antiviral therapy. As noted above, the combination of pegylated interferon alfa and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    is the preferred treatment for patients with mixed cryoglobulinemia due to HCV infection. Although there are no trials specifically in patients with mixed cryoglobulinemia, several observational studies suggest that combination therapy is effective:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A retrospective study compared the outcomes of 32 patients treated with standard (non-pegylated)",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/56/29576?source=see_link\">",
"       interferon alfa-2b",
"      </a>",
"      (3 million international units three times a week) plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"       ribavirin",
"      </a>",
"      with 40 patients treated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/36/24137?source=see_link\">",
"       pegylated interferon alfa-2b",
"      </a>",
"      (1.5",
"      <span class=\"nowrap\">",
"       mcg/kg",
"      </span>",
"      per week) plus ribavirin [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/52/36682/abstract/39\">",
"       39",
"      </a>",
"      ]. These treatments were continued for at least six months (mean duration 18 months with standard interferon and 13 months with pegylated interferon), and patients were followed for a mean of 40 months after discontinuation of antiviral therapy. Six months after completion of antiviral therapy, patients who received pegylated interferon alfa plus ribavirin had somewhat higher rates of clinical remission from cryoglobulinemia (68 versus 56 percent), sustained virologic response (62 verus 53 percent), and disappearance of circulating cryoglobulins (58 versus 31 percent). Notably, severe manifestations were more common in the group receiving standard interferon (27 of 32) as compared with pegylated interferon (15 of 40); severe manifestations were treated with glucocorticoids,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      ,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      plasma exchange.",
"     </li>",
"     <li>",
"      A pilot study of 18 patients with mixed cryoglobulinemia due to HCV infection evaluated the response to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/36/24137?source=see_link\">",
"       pegylated interferon alfa-2b",
"      </a>",
"      (1",
"      <span class=\"nowrap\">",
"       mcg/kg",
"      </span>",
"      per week) plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"       ribavirin",
"      </a>",
"      (1000 mg daily) for 48 weeks, regardless of HCV genotype [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/52/36682/abstract/40\">",
"       40",
"      </a>",
"      ]. This dose of pegylated interferon alfa is lower than what is typically used. Although most patients improved clinically during treatment, eight (44 percent) relapsed virologically and clinically within a few weeks after the end of treatment. At the end of follow-up, only eight patients (44 percent) achieved a sustained virologic response.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In patients with genotype 1, protease inhibitors are also recommended. However, only preliminary efficacy data are available for triple therapy with protease inhibitors, interferon, and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    in patients with mixed cryoglobulinemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/52/36682/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Interferon alfa monotherapy has been replaced by pegylated interferon and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    for treatment of HCV infection in most patients. However, standard (non-pegylated) interferon alfa is also effective in patients who have mixed cryoglobulinemia; the range of therapeutic effects is illustrated by the following examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A randomized, controlled, crossover trial examined the effects of non-pegylated interferon alfa (2 million international units daily for one month and then three times per week for an additional five months) in 26 patients with mixed cryoglobulinemia, 91 percent of whom had circulating HCV RNA [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/52/36682/abstract/42\">",
"       42",
"      </a>",
"      ]. Interferon therapy produced clinical improvements in purpura but did not change the course of peripheral neuropathy. Patients quickly relapsed after discontinuation of interferon.",
"     </li>",
"     <li>",
"      In an open-label trial, 53 patients with mixed cryoglobulinemia were randomly assigned to receive non-pegylated interferon alfa monotherapy (1.5 million international units three times weekly for one week followed by 3 million international units three times weekly for an additional 23 weeks) or to no antiviral therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/52/36682/abstract/43\">",
"       43",
"      </a>",
"      ]. All patients continued to receive other standard medications as indicated. At baseline, 75 percent of patients had glomerulonephritis, and 28 percent had neuropathy; seven patients in each group received concurrent glucocorticoid therapy. Patients who did not receive antiviral therapy had no clinical or serologic improvement. In addition, those patients who received antiviral therapy but did not obtain virologic suppression had no clinical or serologic improvement. Conversely, 60 percent of treated patients who achieved a virologic response had an improvement in clinical parameters such as purpura, serum creatinine, and proteinuria. After cessation of therapy in these patients, both viremia and the clinical manifestations of cryoglobulinemia recurred.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These and other studies suggest an important role of interferon alfa in symptomatic cryoglobulinemia associated with HCV (",
"    <a class=\"graphic graphic_figure graphicRef69711 \" href=\"mobipreview.htm?13/33/13853\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/52/36682/abstract/34,42-51\">",
"     34,42-51",
"    </a>",
"    ]. However, cessation of interferon therapy results in recurrence of viremia and vasculitis in almost all patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H546513\">",
"    <span class=\"h3\">",
"     Duration of therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, the duration of antiviral therapy in patients with HCV infection and mixed cryoglobulinemia is similar to that in patients with HCV infection who do not have mixed cryoglobulinemia. The duration of therapy depends upon a variety of factors, including the HCV genotype, the response to a past attempt at antiviral therapy, and the virologic response to the present attempt at antiviral therapy. A detailed discussion of treatment duration is presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/47/24314?source=see_link\">",
"     \"Treatment regimens for chronic hepatitis C virus genotype 1\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/37/600?source=see_link\">",
"     \"Treatment regimens for chronic hepatitis C virus genotypes 2, 3, and 4\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In general, therapy with pegylated interferon and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    is continued for 48 weeks in patients infected with HCV genotypes 1 and 4, and for 24 weeks in patients infected with HCV genotypes 2 and 3. However, some experts suggest that extended durations (up to 72 weeks for genotypes 1 and 4, and 48 weeks for genotypes 2 and 3) should be considered in nonresponders [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/52/36682/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although data are limited, patients with mixed cryoglobulinemia infected with HCV genotype 1 should receive a protease inhibitor (preferably",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/40/27273?source=see_link\">",
"     boceprevir",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/26/15785?source=see_link\">",
"     \"Studies of telaprevir and boceprevir in the treatment of chronic hepatitis C virus genotype 1\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/47/24314?source=see_link&amp;anchor=H148834010#H148834010\">",
"     \"Treatment regimens for chronic hepatitis C virus genotype 1\", section on 'Treatment regimens'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Response-guided therapy and futility rules are used in patients with mixed cryoglobulinemia due to HCV genotype 1 who are receiving regimens that include a protease inhibitor. In general, we adhere to the rules used in patients without mixed cryoglobulinemia; these rules are presented elsewhere in detail. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/21/27990?source=see_link\">",
"     \"Response-guided therapy for chronic hepatitis C virus infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/47/24314?source=see_link&amp;anchor=H148833684#H148833684\">",
"     \"Treatment regimens for chronic hepatitis C virus genotype 1\", section on 'Monitoring viral load during therapy'",
"    </a>",
"    .) However, if the clinical features of mixed cryoglobulinemia are improving in a patient treated with antiviral therapy, we may continue pegylated interferon and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    for 48 weeks even if futility rules are met.",
"   </p>",
"   <p>",
"    For patients with HCV genotype 2, 3, or 4 infection who are receiving therapy with pegylated interferon and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    , it is acceptable to continue pegylated interferon monotherapy as maintenance treatment if the cryoglobulinemia responds favorably to treatment, despite a lack of virologic response.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1233471\">",
"    <span class=\"h3\">",
"     Monitoring of patients on antiviral therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The frequency of monitoring patients on antiviral treatment is dependent upon multiple variables including, but not limited to:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The disease activity of the cryoglobulinemia",
"     </li>",
"     <li>",
"      The treatment regimen for HCV",
"     </li>",
"     <li>",
"      The individual patient and",
"      <span class=\"nowrap\">",
"       his/her",
"      </span>",
"      comorbidities",
"     </li>",
"     <li>",
"      Presence of cirrhosis with or without portal hypertension",
"     </li>",
"     <li>",
"      The tolerance to therapy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In many patients, we measure a complete blood count and serum chemistries (including renal function, liver function, and blood glucose) weekly during the first two weeks of antiviral therapy, and then monthly thereafter. A thyroid-stimulating hormone should be checked after three months. We obtain HCV viral loads at weeks 4, 12, 24, and 48, and then six months after the completion of therapy. The response-guided therapy and futility rules in hepatitis C rely upon the viral load at certain intervals on therapy. Monitoring of the virologic response and futility rules are presented elsewhere. Patients with cirrhosis and portal hypotension may require more frequent monitoring due to higher risk of side effects. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/21/27990?source=see_link\">",
"     \"Response-guided therapy for chronic hepatitis C virus infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/47/24314?source=see_link&amp;anchor=H148833684#H148833684\">",
"     \"Treatment regimens for chronic hepatitis C virus genotype 1\", section on 'Monitoring viral load during therapy'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    In addition, patients should be monitored for signs of infection, neuropsychiatric side effects (eg, depression), and other side effects of pegylated interferon and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/9/16538?source=see_link\">",
"     \"Management of the side effects of peginterferon and ribavirin being used for treatment of chronic hepatitis C virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are, however, somewhat unique aspects in the follow-up of patients with HCV infection who also have mixed cryoglobulinemia:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Flares of cryoglobulinemia or other immune-mediated events can rarely be induced by treatment with interferon alfa [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/52/36682/abstract/52-55\">",
"       52-55",
"      </a>",
"      ]. As an example, exacerbations of vasculitis due to pegylated interferon have been reported [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/52/36682/abstract/56\">",
"       56",
"      </a>",
"      ]. If an exacerbation of vasculitis occurs in a patient whose disease was previously stable or improving and who does not have serologic evidence of worsening disease (eg, decreasing serum complement), consideration should be given to temporarily lowering the dose of antiviral therapy or, if manifestations are severe, temporarily discontinuing therapy. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?16/9/16538?source=see_link&amp;anchor=H17#H17\">",
"       \"Management of the side effects of peginterferon and ribavirin being used for treatment of chronic hepatitis C virus infection\", section on 'Dermatologic complications'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Similarly, interferon can produce side effects that may mimic some of the manifestations of cryoglobulinemia, such as arthralgias, fever, or rash. In such cases, antiviral therapy may be temporarily discontinued provided a protease inhibitor is not part of the regimen. For those patients whose regimen includes a protease inhibitor who temporarily stop therapy, the protease inhibitor should not be restarted. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?16/9/16538?source=see_link\">",
"       \"Management of the side effects of peginterferon and ribavirin being used for treatment of chronic hepatitis C virus infection\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      HCV viral particles may be incorporated into the cryoprecipitate and centrifuged during preparation of serum samples or may precipitate from the serum during storage. To prevent falsely low measurements of the viral load, blood specimens may require special handling. To ensure accurate quantitation of the HCV viral load, specimens should be kept at 37 degrees centigrade during serum preparation, and any cryoprecipitate should be dissolved or suspended into the serum before measuring the viral load.",
"     </li>",
"     <li>",
"      In patients receiving plasmapheresis, blood sample collection obtained to measure the viral load should be delayed until after re-equilibration, which may take several hours.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Anti-HBV therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although HCV infection is the major cause of essential mixed cryoglobulinemia, some cases (as high as 15 percent in one series) are associated with HBV infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/52/36682/abstract/44\">",
"     44",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/15/34040?source=see_link\">",
"     \"Clinical manifestations and diagnosis of the mixed cryoglobulinemia syndrome (essential mixed cryoglobulinemia)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In patients with mixed cryoglobulinemia due to HBV infection, treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/55/29557?source=see_link\">",
"     entecavir",
"    </a>",
"    is usually preferred in view of its antiviral efficacy, low propensity for drug resistance, and low risk for nephrotoxicity. The best data supporting these",
"    <span class=\"nowrap\">",
"     nucleoside/nucleotide",
"    </span>",
"    analogs in HBV-associated mixed cryoglobulinemia come from case reports that describe patients who achieved remission with entecavir or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/52/36682/abstract/57-60\">",
"     57-60",
"    </a>",
"    ]. Other",
"    <span class=\"nowrap\">",
"     nucleoside/nucleotide",
"    </span>",
"    analogs, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/44/10949?source=see_link\">",
"     adefovir",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/15/3317?source=see_link\">",
"     telbivudine",
"    </a>",
"    , and lamivudine, have been used but have a higher risk of resistance and, with adefovir, a higher risk of nephrotoxicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/52/36682/abstract/57,58,61\">",
"     57,58,61",
"    </a>",
"    ]. The use of",
"    <span class=\"nowrap\">",
"     nucleoside/nucleotide",
"    </span>",
"    analogs in patients with HBV infection, as well as the dosing of these drugs in patients with reduced renal function, is described in detail elsewhere (",
"    <a class=\"graphic graphic_table graphicRef58520 \" href=\"mobipreview.htm?26/32/27149\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef71024 \" href=\"mobipreview.htm?15/56/16269\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/51/24378?source=see_link&amp;anchor=H6#H6\">",
"     \"Overview of the management of hepatitis B and case examples\", section on 'Who should be treated and how'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/30/11752?source=see_link\">",
"     \"Entecavir in the treatment of chronic hepatitis B virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Interferon alfa also has activity against HBV infection, and pegylated interferon could theoretically be used in patients with non-cirrhotic chronic hepatitis B and non-severe cryoglobulinemia, although there are no data available to support this approach. In addition, using the oral",
"    <span class=\"nowrap\">",
"     nucleoside/nucleotide",
"    </span>",
"    agents avoids the risk of immune-mediated events or disease flares associated with interferon [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/52/36682/abstract/52-55\">",
"     52-55",
"    </a>",
"    ]. Thus, we generally favor the use of",
"    <span class=\"nowrap\">",
"     nucleoside/nucleotide",
"    </span>",
"    analogs over pegylated interferon for treatment of HBV infection in the setting of cryoglobulinemia.",
"   </p>",
"   <p>",
"    In patients with mixed cryoglobulinemia due to HBV infection who have severe manifestations (eg, glomerulonephritis, cutaneous ulcers, progressive neuropathy), we recommend immunosuppressive therapy with glucocorticoids;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    <strong>",
"     therapy should only be used in selected patients with suppressed viremia and without active hepatitis",
"    </strong>",
"    .",
"   </p>",
"   <p>",
"    Patients with chronic HBV infection and cryoglobulinemia should be started on treatment with an antiviral medication",
"    <strong>",
"     as soon as possible",
"    </strong>",
"    when immunosuppressive therapy is planned, regardless of HBe and HBV DNA status. This contrasts with our suggestion to delay antiviral therapy in patients with HCV infection when immunosuppression is planned. (See",
"    <a class=\"local\" href=\"#H17909481\">",
"     'Immunosuppressive therapy for severe mixed cryoglobulinemia'",
"    </a>",
"    above.)",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     Rituximab",
"    </a>",
"    therapy could be considered, as mentioned above, for patients who do not have chronic active hepatitis and who have controlled viremia. However, the published experience with rituximab for HBV-associated mixed cryoglobulinemia is limited, and there is potential for fatal complications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/52/36682/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Beginning antiviral therapy (preferably with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/55/29557?source=see_link\">",
"     entecavir",
"    </a>",
"    ) as soon as possible when immunosuppression is planned serves two purposes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      It can protect against a HBV flare, especially when",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      is used. Rituximab therapy should",
"      <strong>",
"       not",
"      </strong>",
"      be started in patients with chronic HBV unless antiviral therapy is also given and not in patients with chronic active hepatitis. Otherwise, potentially fatal hepatitis may result. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/25/26009?source=see_link\">",
"       \"Hepatitis B virus reactivation associated with immunosuppression\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      It can protect against the increased HBV replication associated with glucocorticoid therapy. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/25/26009?source=see_link\">",
"       \"Hepatitis B virus reactivation associated with immunosuppression\"",
"      </a>",
"      .) &nbsp;",
"     </li>",
"     <li>",
"      HBV viral suppression may induce remission of mixed cryoglobulinemia.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the absence of data, we suggest that antiviral therapy in such patients be continued indefinitely. Monitoring of chronic HBV infection in patients treated with antiviral therapy is presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/30/11752?source=see_link\">",
"     \"Entecavir in the treatment of chronic hepatitis B virus infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/51/24378?source=see_link\">",
"     \"Overview of the management of hepatitis B and case examples\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6575895\">",
"    <span class=\"h2\">",
"     Autoimmune disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mixed cryoglobulinemia can occur in patients with various autoimmune disorders, such as Sj&ouml;gren syndrome, systemic lupus erythematosus, or rheumatoid arthritis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/15/34040?source=see_link\">",
"     \"Clinical manifestations and diagnosis of the mixed cryoglobulinemia syndrome (essential mixed cryoglobulinemia)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Such patients should be treated for their underlying disorder. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/14/2282?source=see_link\">",
"     \"Treatment of systemic and extraglandular manifestations of Sj&ouml;gren&rsquo;s syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/38/41578?source=see_link\">",
"     \"Overview of the therapy and prognosis of systemic lupus erythematosus in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In patients with mixed cryoglobulinemia due to autoimmune disorders who have severe vasculitic manifestations (eg, glomerulonephritis, cutaneous ulcers, progressive neuropathy), we also suggest combination therapy with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    (or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    as an alternative) and glucocorticoids, as mentioned above. (See",
"    <a class=\"local\" href=\"#H17909481\">",
"     'Immunosuppressive therapy for severe mixed cryoglobulinemia'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6575986\">",
"    <span class=\"h2\">",
"     Lymphoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mixed cryoglobulinemia can occur in patients with non-Hodgkin lymphoma, although cryoglobulinemia occurring with lymphoma are usually type I. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/15/34040?source=see_link\">",
"     \"Clinical manifestations and diagnosis of the mixed cryoglobulinemia syndrome (essential mixed cryoglobulinemia)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Such patients should be referred to an appropriate specialist and treated for the underlying malignancy. An overview of such protocols, with links to discussions of specific lymphomas, is presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/44/24258?source=see_link\">",
"     \"Treatment protocols for lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     Rituximab",
"    </a>",
"    is commonly used in the treatment of B-cell lymphomas typically associated with mixed cryoglobulinemia, which may be helpful for treating the malignancy as well as the autoimmune disorder [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/52/36682/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H571879\">",
"    <span class=\"h2\">",
"     Idiopathic disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Occasional patients with mixed cryoglobulinemia may have no identifiable underlying disorder despite an extensive evaluation. Therapy depends upon the severity of the clinical manifestations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Severe manifestations (eg, glomerulonephritis, cutaneous ulcers, progressive neuropathy) &ndash; In such patients, the immunosuppressive protocols outlined above, including the use of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      , should be followed. (See",
"      <a class=\"local\" href=\"#H17909552\">",
"       'Choice of immunosuppressive therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Mild to moderate manifestations &ndash; Such patients can be managed with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/13/32983?source=see_link\">",
"       colchicine",
"      </a>",
"      (1 to 2",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      orally) or low doses of glucocorticoids (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      , 10 to 25",
"      <span class=\"nowrap\">",
"       mg/day).",
"      </span>",
"      If prednisone is used, we attempt to taper the dose to less than 10",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      by six months, depending upon the clinical response [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/52/36682/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H571871\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The short-term prognosis in patients with very severe manifestations is generally poor, particularly for the patients who develop acute pulmonary hemorrhage, intestinal vasculitis with gastrointestinal hemorrhage or ischemia, or rapidly progressive glomerulonephritis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/52/36682/abstract/25,64\">",
"     25,64",
"    </a>",
"    ]. In one series of 29 patients with these manifestations, for example, the mortality was 66 percent during an average follow-up of 3.6 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/52/36682/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The long-term prognosis of patients with HCV-associated mixed cryoglobulinemia syndrome appears to have improved with the use of antiviral therapy, although long-term follow-up of cohorts receiving modern therapy (ie, pegylated interferon,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    , with or without protease inhibitors) is not available. However, the introduction of interferon monotherapy in some patients illustrates an improving trend:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A report of 105 patients with renal involvement (85 percent of whom were anti-HCV antibody positive) provided data on the long-term prognosis",
"      <strong>",
"       prior",
"      </strong>",
"      to treatment with interferon [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/52/36682/abstract/65\">",
"       65",
"      </a>",
"      ]. The 10-year patient survival was 49 percent after the diagnosis, with most deaths attributed to cardiovascular or hepatic disease or infection. Only 14 percent developed end-stage renal disease (ESRD) at 10 years, possibly because patients with severe disease died from other causes before the onset of ESRD.",
"     </li>",
"     <li>",
"      A study of 146 patients with mixed cryoglobulinemia and renal involvement were followed for over 10 years in an Italian cohort that began in 1995; 38 percent of patients received interferon monotherapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/52/36682/abstract/1\">",
"       1",
"      </a>",
"      ]. The 10-year patient survival was approximately 80 percent. Those with worse renal function at baseline had a worse prognosis. Cardiovascular disease was the cause of death in more than 60 percent of patients.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As noted above, not all patients with HCV infection and cryoglobulinemia respond to interferon treatment. In addition, the vasculitic manifestations of cryoglobulinemia in patients who do have a virologic response to antiviral therapy may persist or recur after cessation of antiviral therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/52/36682/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The prognosis of patients with mixed cryoglobulinemia syndrome who do not have a viral etiology may be similar or worse than in patients with a chronic viral infection. In a French cohort of 242 patients with non-infectious mixed cryoglobulinemia, the one-, two-, five-, and ten-year patient survival rates were 91, 89, 79, and 65 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/52/36682/abstract/67\">",
"     67",
"    </a>",
"    ]. The four independent predictors of death in this cohort were age greater than 65 years, renal involvement (with reduced renal function), pulmonary involvement, and gastrointestinal involvement. The 10-year survival among patients with renal impairment was approximately 50 percent, similar to patients with HCV-associated mixed cryoglobulinemia and renal involvement prior to the availability of interferon therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     END-STAGE RENAL DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Those patients who progress to end-stage renal disease (ESRD) can be treated with dialysis or renal transplantation. Survival on either hemodialysis or peritoneal dialysis is broadly similar to that in patients with other renal diseases.",
"   </p>",
"   <p>",
"    Renal transplantation has been successfully performed in mixed cryoglobulinemia. Clinically significant disease can recur in 50 to 70 percent of cases, even in patients in clinical and serologic remission at the time of transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/52/36682/abstract/27,68,69\">",
"     27,68,69",
"    </a>",
"    ]. Affected patients present with findings similar to those in the primary disease: purpura, hypocomplementemia, hematuria, proteinuria, and renal impairment. These findings, however, should not deter transplantation since most patients do not lose the graft to recurrent disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/52/36682/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is potential theoretical concern that maintenance immunosuppressive therapy after transplantation might exacerbate underlying HCV infection, but this has not proven to be a major problem [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/52/36682/abstract/68\">",
"     68",
"    </a>",
"    ]. The approach to therapy in patients after renal transplantation is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/53/3928?source=see_link\">",
"     \"Renal disease associated with hepatitis C virus after renal transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1906291\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The mixed cryoglobulinemia syndrome is most often induced by hepatitis C virus (HCV) infection and, occasionally, hepatitis B. It can also be associated with autoimmune or lymphoproliferative disorders and, rarely, can be idiopathic. Typically, it follows a chronic, smoldering course. Infrequently, mixed cryoglobulinemia may present with a rapidly progressive or even life-threatening course. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The general approach to therapy in patients with mixed cryoglobulinemia syndrome includes two broad principles (see",
"      <a class=\"local\" href=\"#H2\">",
"       'General approach to therapy'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Initial immunosuppressive therapy &ndash; Immunosuppression is provided as initial therapy in those patients identified as having a rapidly progressive, organ-threatening, or life-threatening course, regardless of the etiology of the mixed cryoglobulinemia. Immunosuppressive therapy usually combines a short course of glucocorticoids with either",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      and, in some patients, plasmapheresis. (See",
"      <a class=\"local\" href=\"#H17909481\">",
"       'Immunosuppressive therapy for severe mixed cryoglobulinemia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment of the underlying disease &ndash; All patients should receive therapy directed against the underlying etiology of the mixed cryoglobulinemia. As examples, patients with HCV should receive antiviral therapy, while patients with an underlying lymphoproliferative disorder should receive appropriate disease-specific therapy. In some cases, this will involve continuation of immunosuppression for a prolonged period. (See",
"      <a class=\"local\" href=\"#H17909507\">",
"       'Treat the underlying disorder in all patients'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients with mixed cryoglobulinemia syndrome and severe disease-associated manifestations, we recommend immunosuppressive therapy plus treatment of the underlying etiology, rather than therapy directed at the underlying etiology alone (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Severe disease-associated manifestations include (see",
"      <a class=\"local\" href=\"#H17909544\">",
"       'Patient selection'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Glomerulonephritis associated with either a rapidly progressive course",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      nephrotic range proteinuria",
"     </li>",
"     <li>",
"      Severe digital ischemia threatening amputation",
"     </li>",
"     <li>",
"      Gastrointestinal vasculitis associated with abdominal pain",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      gastrointestinal bleeding",
"     </li>",
"     <li>",
"      Rapidly progressive neuropathy",
"     </li>",
"     <li>",
"      Central nervous system vasculitis that may present as a stroke or acute cognitive impairment",
"     </li>",
"     <li>",
"      Pulmonary vasculitis associated with diffuse alveolar hemorrhage or respiratory failure",
"     </li>",
"     <li>",
"      Heart failure",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients with mixed cryoglobulinemia due to HIV or HBV infections, antiviral therapy should always be initiated before or at the same time as immunosuppressive therapy. (See",
"      <a class=\"local\" href=\"#H17909481\">",
"       'Immunosuppressive therapy for severe mixed cryoglobulinemia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In most patients selected for initial immunosuppressive therapy, we suggest",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      rather than other immunosuppressive drugs such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      or glucocorticoids alone (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). In addition, we suggest pulse glucocorticoid therapy followed by a rapid taper in most patients rather than prolonged glucocorticoid therapy or no glucocorticoid therapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). In those patients with life-threatening disease or cryoglobulinemia-associated hyperviscosity syndrome, we also suggest plasmapheresis in addition to immunosuppressive therapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H17909552\">",
"       'Choice of immunosuppressive therapy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H571919\">",
"       'Preference for rituximab'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3\">",
"       'Role of plasma exchange'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      , glucocorticoid, and plasmapheresis regimens used are discussed above. (See",
"      <a class=\"local\" href=\"#H571927\">",
"       'Rituximab regimen'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H1233191\">",
"       'Glucocorticoid regimen'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'Plasma exchange prescription'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We would",
"      <strong>",
"       not",
"      </strong>",
"      use",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      to treat mixed cryoglobulinemia in the following patients (see",
"      <a class=\"local\" href=\"#H17909552\">",
"       'Choice of immunosuppressive therapy'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      In patients with HIV infection who are not receiving highly active antiretroviral therapy (HAART). Such patients are at high risk for enhanced viral replication as a result of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      therapy. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?35/24/36234?source=see_link\">",
"       \"Selecting antiretroviral regimens for the treatment naive HIV-infected patient\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In patients with HBV infection who are not receiving antiviral therapy or have chronic active hepatitis. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Anti-HBV therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The use of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      therapy in patients with mixed cryoglobulinemia, particularly in patients with HCV or HBV infection, carries the risk of enhancing viral replication. In patients with organ-threatening or life-threatening disease, cyclophosphamide therapy may be used as an alternative to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      if rituximab therapy is unavailable, fails to produce a clinical response, or is not tolerated. When used, cyclophosphamide can be used in combination with glucocorticoids with or without plasma exchange, similar to rituximab. The cyclophosphamide dose in such patients is 2",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day orally for two to four months. The initial dose should be adjusted according to the age and glomerular filtration rate (GFR). (See",
"      <a class=\"local\" href=\"#H1230577\">",
"       'Role of cyclophosphamide'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Prophylaxis against opportunistic infections, such as Pneumocystis pneumonia, should be provided in patients with mixed cryoglobulinemia who are receiving immunosuppressive therapy. Patients should also receive age-appropriate immunizations, ideally several weeks before the initiation of immunosuppression. (See",
"      <a class=\"local\" href=\"#H1576718960\">",
"       'Antimicrobial prophylaxis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The following approach to therapy applies to most patients with mixed cryoglobulinemia due to HCV infection (see",
"      <a class=\"local\" href=\"#H5\">",
"       'Therapy for HCV infection'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      In general, antiviral therapy should be delayed for one to four months in patients with severe disease who require initial therapy with immunosuppressant agents. (See",
"      <a class=\"local\" href=\"#H1233455\">",
"       'Initiation of HCV therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The specific antiviral drugs and doses used depend upon the HCV genotype (ie, pegylated interferon and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"       ribavirin",
"      </a>",
"      for genotypes 2, 3, and 4, with the addition of a either",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/40/27273?source=see_link\">",
"       boceprevir",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/6/20585?source=see_link\">",
"       telaprevir",
"      </a>",
"      for genotype 1) and also upon the renal function. Antiviral therapy is contraindicated in patients with decompensated cirrhosis. (See",
"      <a class=\"local\" href=\"#H1233463\">",
"       'Drugs and dosing in HCV therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The duration of antiviral therapy is based upon the HCV genotype (ie, genotype 1 versus genotypes 2, 3, and 4), prior treatment response, tolerance to treatment, and the clinical and laboratory response to treatment. In general we favor 48 weeks of therapy in patients with genotype 1 or genotype 4, and 24 weeks in patients with genotype 2 and genotype 3. (See",
"      <a class=\"local\" href=\"#H546513\">",
"       'Duration of therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We generally follow renal and hepatic function weekly during the first two weeks of antiviral therapy, and then monthly thereafter. HCV viral loads should be obtained at weeks 4, 12, 24, and 48, and then six months after the completion of therapy. The frequency of follow-up visits in the clinic depends upon the cryoglobulinemia disease activity, treatment regimen, comorbidities, and tolerance of therapy. Patients with cirrhosis and portal hypertension may require more frequent monitoring due to higher risk of side effects. (See",
"      <a class=\"local\" href=\"#H1233471\">",
"       'Monitoring of patients on antiviral therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients with mixed cryoglobulinemia due to HBV infection, treatment with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/55/29557?source=see_link\">",
"       entecavir",
"      </a>",
"      is usually preferred in view of its antiviral efficacy, low propensity for drug resistance, and low risk for nephrotoxicity. Antiviral therapy is usually continued indefinitely. In patients with mixed cryoglobulinemia due to HBV infection who have severe manifestations (eg, glomerulonephritis, cutaneous ulcers, progressive neuropathy), initial immunosuppressive therapy with glucocorticoids can be used. However, antiviral therapy should be initiated",
"      <strong>",
"       as soon as possible",
"      </strong>",
"      when immunosuppressive therapy is planned (preferably prior to the initiation of immunosuppressive therapy), regardless of HBe and HBV DNA status. If addition of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      is considered, antiviral therapy in mandatory and rituximab should not be used in patients with chronic active hepatitis. Otherwise, potentially fatal hepatitis may result. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Anti-HBV therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with mixed cryoglobulinemia due to autoimmune disorders who have severe vasculitic manifestations (eg, glomerulonephritis, cutaneous ulcers, progressive neuropathy) should receive immunosuppressive therapy with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      (or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      as an alternative) and glucocorticoids. The regimen is similar to the regimen used for all other patients with mixed cryoglobulinemia and severe manifestations. In patients with mild to moderate clinical manifestations, therapy is directed at the underlying etiology. (See",
"      <a class=\"local\" href=\"#H6575895\">",
"       'Autoimmune disorders'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with mixed cryoglobulinemia due to lymphoma should be referred to an appropriate specialist and treated for the underlying malignancy.",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"       Rituximab",
"      </a>",
"      is commonly used in the treatment of B-cell lymphomas typically associated with mixed cryoglobulinemia. (See",
"      <a class=\"local\" href=\"#H6575986\">",
"       'Lymphoma'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Occasional patients with mixed cryoglobulinemia may have no identifiable underlying disorder. Therapy depends upon the severity of the clinical manifestations (see",
"      <a class=\"local\" href=\"#H571879\">",
"       'Idiopathic disease'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Severe manifestations (eg, glomerulonephritis, cutaneous ulcers, progressive neuropathy) &ndash; In such patients, the immunosuppressive protocols outlined above should be followed. (See",
"      <a class=\"local\" href=\"#H17909552\">",
"       'Choice of immunosuppressive therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Mild to moderate manifestation &ndash; Such patients can be managed with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/13/32983?source=see_link\">",
"       colchicine",
"      </a>",
"      (1 to 2",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      orally) or low doses of glucocorticoids (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      , 10 to 25",
"      <span class=\"nowrap\">",
"       mg/day).",
"      </span>",
"      If prednisone is used, we attempt to taper the dose to less than 10",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      by six months, depending upon patient response.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The 10-year survival among patients with mixed cryoglobulinemia varies depending upon organ involvement and the underlying cause of the disorder, ranging from 50 to 80 percent. However, the short-term prognosis in patients with very severe manifestations is generally poor, particularly for the patients who develop acute pulmonary hemorrhage, intestinal vasculitis with gastrointestinal hemorrhage or ischemia, or rapidly progressive glomerulonephritis. (See",
"      <a class=\"local\" href=\"#H571871\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/52/36682/abstract/1\">",
"      Roccatello D, Fornasieri A, Giachino O, et al. Multicenter study on hepatitis C virus-related cryoglobulinemic glomerulonephritis. Am J Kidney Dis 2007; 49:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/52/36682/abstract/2\">",
"      Gorevic PD, Kassab HJ, Levo Y, et al. Mixed cryoglobulinemia: clinical aspects and long-term follow-up of 40 patients. Am J Med 1980; 69:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/52/36682/abstract/3\">",
"      D'Amico G, Colasanti G, Ferrario F, Sinico RA. Renal involvement in essential mixed cryoglobulinemia. Kidney Int 1989; 35:1004.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/52/36682/abstract/4\">",
"      Frankel AH, Singer DR, Winearls CG, et al. Type II essential mixed cryoglobulinaemia: presentation, treatment and outcome in 13 patients. Q J Med 1992; 82:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/52/36682/abstract/5\">",
"      Bryce AH, Kyle RA, Dispenzieri A, Gertz MA. Natural history and therapy of 66 patients with mixed cryoglobulinemia. Am J Hematol 2006; 81:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/52/36682/abstract/6\">",
"      Pietrogrande M, De Vita S, Zignego AL, et al. Recommendations for the management of mixed cryoglobulinemia syndrome in hepatitis C virus-infected patients. Autoimmun Rev 2011; 10:444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/52/36682/abstract/7\">",
"      Sandri AM, Elewa U, Poterucha JJ, Fervenza FC. Treatment of hepatitis C-mediated glomerular disease. Nephron Clin Pract 2011; 119:c121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/52/36682/abstract/8\">",
"      De Vita S, Quartuccio L, Isola M, et al. A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis. Arthritis Rheum 2012; 64:843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/52/36682/abstract/9\">",
"      Saadoun D, Resche Rigon M, Sene D, et al. Rituximab plus Peg-interferon-alpha/ribavirin compared with Peg-interferon-alpha/ribavirin in hepatitis C-related mixed cryoglobulinemia. Blood 2010; 116:326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/52/36682/abstract/10\">",
"      Ferri C, Cacoub P, Mazzaro C, et al. Treatment with rituximab in patients with mixed cryoglobulinemia syndrome: results of multicenter cohort study and review of the literature. Autoimmun Rev 2011; 11:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/52/36682/abstract/11\">",
"      Landau DA, Saadoun D, Halfon P, et al. Relapse of hepatitis C virus-associated mixed cryoglobulinemia vasculitis in patients with sustained viral response. Arthritis Rheum 2008; 58:604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/52/36682/abstract/12\">",
"      Quartuccio L, De Marchi G, Fabris M, De Vita S. Development of type II mixed cryoglobulinaemic syndrome after effective and persistent hepatitis C virus eradication. Rheumatology (Oxford) 2007; 46:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/52/36682/abstract/13\">",
"      Cavallo R, Roccatello D, Menegatti E, et al. Rituximab in cryoglobulinemic peripheral neuropathy. J Neurol 2009; 256:1076.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/52/36682/abstract/14\">",
"      Terrier B, Krastinova E, Marie I, et al. Management of noninfectious mixed cryoglobulinemia vasculitis: data from 242 cases included in the CryoVas survey. Blood 2012; 119:5996.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/52/36682/abstract/15\">",
"      Sneller MC, Hu Z, Langford CA. A randomized controlled trial of rituximab following failure of antiviral therapy for hepatitis C virus-associated cryoglobulinemic vasculitis. Arthritis Rheum 2012; 64:835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/52/36682/abstract/16\">",
"      Quartuccio L, Soardo G, Romano G, et al. Rituximab treatment for glomerulonephritis in HCV-associated mixed cryoglobulinaemia: efficacy and safety in the absence of steroids. Rheumatology (Oxford) 2006; 45:842.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/52/36682/abstract/17\">",
"      Roccatello D, Baldovino S, Rossi D, et al. Long-term effects of anti-CD20 monoclonal antibody treatment of cryoglobulinaemic glomerulonephritis. Nephrol Dial Transplant 2004; 19:3054.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/52/36682/abstract/18\">",
"      Roccatello D, Baldovino S, Rossi D, et al. Rituximab as a therapeutic tool in severe mixed cryoglobulinemia. Clin Rev Allergy Immunol 2008; 34:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/52/36682/abstract/19\">",
"      Petrarca A, Rigacci L, Caini P, et al. Safety and efficacy of rituximab in patients with hepatitis C virus-related mixed cryoglobulinemia and severe liver disease. Blood 2010; 116:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/52/36682/abstract/20\">",
"      Sansonno D, De Re V, Lauletta G, et al. Monoclonal antibody treatment of mixed cryoglobulinemia resistant to interferon alpha with an anti-CD20. Blood 2003; 101:3818.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/52/36682/abstract/21\">",
"      Basse G, Ribes D, Kamar N, et al. Rituximab therapy for de novo mixed cryoglobulinemia in renal transplant patients. Transplantation 2005; 80:1560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/52/36682/abstract/22\">",
"      Visentini M, Ludovisi S, Petrarca A, et al. A phase II, single-arm multicenter study of low-dose rituximab for refractory mixed cryoglobulinemia secondary to hepatitis C virus infection. Autoimmun Rev 2011; 10:714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/52/36682/abstract/23\">",
"      Landau DA, Scerra S, Sene D, et al. Causes and predictive factors of mortality in a cohort of patients with hepatitis C virus-related cryoglobulinemic vasculitis treated with antiviral therapy. J Rheumatol 2010; 37:615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/52/36682/abstract/24\">",
"      Valbonesi M, Florio G, Montani F, Mosconi L. A method for the study of cryoglobulin solubilization curves at 37 degrees C. Preliminary studies and application to plasma exchange in cryoglobulinemic syndromes. Int J Artif Organs 1983; 6:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/52/36682/abstract/25\">",
"      Ramos-Casals M, Robles A, Brito-Zer&oacute;n P, et al. Life-threatening cryoglobulinemia: clinical and immunological characterization of 29 cases. Semin Arthritis Rheum 2006; 36:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/52/36682/abstract/26\">",
"      Rockx MA, Clark WF. Plasma exchange for treating cryoglobulinemia: a descriptive analysis. Transfus Apher Sci 2010; 42:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/52/36682/abstract/27\">",
"      Madore F, Lazarus JM, Brady HR. Therapeutic plasma exchange in renal diseases. J Am Soc Nephrol 1996; 7:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/52/36682/abstract/28\">",
"      Guillevin L, Pagnoux C. Indications of plasma exchanges for systemic vasculitides. Ther Apher Dial 2003; 7:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/52/36682/abstract/29\">",
"      Szczepiorkowski ZM, Winters JL, Bandarenko N, et al. Guidelines on the use of therapeutic apheresis in clinical practice--evidence-based approach from the Apheresis Applications Committee of the American Society for Apheresis. J Clin Apher 2010; 25:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/52/36682/abstract/30\">",
"      Campise M, Tarantino A. Glomerulonephritis in mixed cryoglobulinaemia: what treatment? Nephrol Dial Transplant 1999; 14:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/52/36682/abstract/31\">",
"      Evans TW, Nicholls AJ, Shortland JR, et al. Acute renal failure in essential mixed cryoglobulinemia: precipitation and reversal by plasma exchange. Clin Nephrol 1984; 21:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/52/36682/abstract/32\">",
"      Mazzi G, Raineri A, Zucco M, et al. Plasma-exchange in chronic peripheral neurological disorders. Int J Artif Organs 1999; 22:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/52/36682/abstract/33\">",
"      Mukhtyar C, Guillevin L, Cid MC, et al. EULAR recommendations for the management of primary small and medium vessel vasculitis. Ann Rheum Dis 2009; 68:310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/52/36682/abstract/34\">",
"      Dammacco F, Sansonno D, Han JH, et al. Natural interferon-alpha versus its combination with 6-methyl-prednisolone in the therapy of type II mixed cryoglobulinemia: a long-term, randomized, controlled study. Blood 1994; 84:3336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/52/36682/abstract/35\">",
"      Fong TL, Valinluck B, Govindarajan S, et al. Short-term prednisone therapy affects aminotransferase activity and hepatitis C virus RNA levels in chronic hepatitis C. Gastroenterology 1994; 107:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/52/36682/abstract/36\">",
"      Calleja JL, Albillos A, Cacho G, et al. Interferon and prednisone therapy in chronic hepatitis C with non-organ-specific antibodies. J Hepatol 1996; 24:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/52/36682/abstract/37\">",
"      Ghany MG, Nelson DR, Strader DB, et al. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 2011; 54:1433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/52/36682/abstract/38\">",
"      Kidney Disease: Improving Global Outcomes (KDIGO). KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease. Kidney Int Suppl 2008; :S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/52/36682/abstract/39\">",
"      Saadoun D, Resche-Rigon M, Thibault V, et al. Antiviral therapy for hepatitis C virus--associated mixed cryoglobulinemia vasculitis: a long-term followup study. Arthritis Rheum 2006; 54:3696.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/52/36682/abstract/40\">",
"      Mazzaro C, Zorat F, Caizzi M, et al. Treatment with peg-interferon alfa-2b and ribavirin of hepatitis C virus-associated mixed cryoglobulinemia: a pilot study. J Hepatol 2005; 42:632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/52/36682/abstract/41\">",
"      Saadoun A, Pohl S, Lebray Sr. P. Peg-IFNa/Ribavirin/Protease Inhibitor Combination Is Highly Effective in HCV-Mixed Cryoglobulinemia Vasculitis (abstr). Arthritis Rheum 2012; 64:S708.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/52/36682/abstract/42\">",
"      Ferri C, Marzo E, Longombardo G, et al. Interferon-alpha in mixed cryoglobulinemia patients: a randomized, crossover-controlled trial. Blood 1993; 81:1132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/52/36682/abstract/43\">",
"      Misiani R, Bellavita P, Fenili D, et al. Interferon alfa-2a therapy in cryoglobulinemia associated with hepatitis C virus. N Engl J Med 1994; 330:751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/52/36682/abstract/44\">",
"      Lunel F, Musset L, Cacoub P, et al. Cryoglobulinemia in chronic liver diseases: role of hepatitis C virus and liver damage. Gastroenterology 1994; 106:1291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/52/36682/abstract/45\">",
"      Misiani R, Bellavita P, Fenili D, et al. Hepatitis C virus infection in patients with essential mixed cryoglobulinemia. Ann Intern Med 1992; 117:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/52/36682/abstract/46\">",
"      Johnson RJ, Willson R, Yamabe H, et al. Renal manifestations of hepatitis C virus infection. Kidney Int 1994; 46:1255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/52/36682/abstract/47\">",
"      Casato M, Lagan&agrave; B, Antonelli G, et al. Long-term results of therapy with interferon-alpha for type II essential mixed cryoglobulinemia. Blood 1991; 78:3142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/52/36682/abstract/48\">",
"      Poynard T, Bedossa P, Chevallier M, et al. A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. Multicenter Study Group. N Engl J Med 1995; 332:1457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/52/36682/abstract/49\">",
"      Poynard T, Leroy V, Cohard M, et al. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration. Hepatology 1996; 24:778.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/52/36682/abstract/50\">",
"      Casato M, Agnello V, Pucillo LP, et al. Predictors of long-term response to high-dose interferon therapy in type II cryoglobulinemia associated with hepatitis C virus infection. Blood 1997; 90:3865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/52/36682/abstract/51\">",
"      Agnello V, Chung RT, Kaplan LM. A role for hepatitis C virus infection in type II cryoglobulinemia. N Engl J Med 1992; 327:1490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/52/36682/abstract/52\">",
"      La Civita L, Zignego AL, Lombardini F, et al. Exacerbation of peripheral neuropathy during alpha-interferon therapy in a patient with mixed cryoglobulinemia and hepatitis B virus infection. J Rheumatol 1996; 23:1641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/52/36682/abstract/53\">",
"      Harl&eacute; JR, Disdier P, Pelletier J, et al. Dramatic worsening of hepatitis C virus-related cryoglobulinemia subsequent to treatment with interferon alfa. JAMA 1995; 274:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/52/36682/abstract/54\">",
"      Friedman G, Mehta S, Sherker AH. Fatal exacerbation of hepatitis C-related cryoglobulinemia with interferon-alpha therapy. Dig Dis Sci 1999; 44:1364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/52/36682/abstract/55\">",
"      Raanani P, Ben-Bassat I. Immune-mediated complications during interferon therapy in hematological patients. Acta Haematol 2002; 107:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/52/36682/abstract/56\">",
"      Batisse D, Karmochkine M, Jacquot C, et al. Sustained exacerbation of cryoglobulinaemia-related vasculitis following treatment of hepatitis C with peginterferon alfa. Eur J Gastroenterol Hepatol 2004; 16:701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/52/36682/abstract/57\">",
"      Sawabe T, Uenotsuchi T, Imafuku S, et al. Remission of hepatitis B virus-related vasculitis with lamivudine. Ann Intern Med 2004; 140:672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/52/36682/abstract/58\">",
"      Stecevic V, Pevzner MM, Gordon SC. Successful treatment of hepatitis B-associated vasculitis with lamivudine. J Clin Gastroenterol 2003; 36:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/52/36682/abstract/59\">",
"      Kawakami T, Ooka S, Mizoguchi M, et al. Remission of hepatitis B virus-related cryoglobulinemic vasculitis with entecavir. Ann Intern Med 2008; 149:911.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/52/36682/abstract/60\">",
"      Enomoto M, Nakanishi T, Nakamishi T, et al. Entecavir to treat hepatitis B-associated cryoglobulinemic vasculitis. Ann Intern Med 2008; 149:912.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/52/36682/abstract/61\">",
"      Boglione L, D'Avolio A, Cariti G, Di Perri G. Telbivudine in the treatment of hepatitis B-associated cryoglobulinemia. J Clin Virol 2013; 56:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/52/36682/abstract/62\">",
"      Pasquet F, Combarnous F, Macgregor B, et al. Safety and efficacy of rituximab treatment for vasculitis in hepatitis B virus-associated type II cryoglobulinemia: a case report. J Med Case Rep 2012; 6:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/52/36682/abstract/63\">",
"      Saadoun D, Pineton de Chambrun M, Hermine O, et al. Using rituximab plus fludarabine and cyclophosphamide as a treatment for refractory mixed cryoglobulinemia associated with lymphoma. Arthritis Care Res (Hoboken) 2013; 65:643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/52/36682/abstract/64\">",
"      Ferri C, Sebastiani M, Giuggioli D, et al. Mixed cryoglobulinemia: demographic, clinical, and serologic features and survival in 231 patients. Semin Arthritis Rheum 2004; 33:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/52/36682/abstract/65\">",
"      Tarantino A, Campise M, Banfi G, et al. Long-term predictors of survival in essential mixed cryoglobulinemic glomerulonephritis. Kidney Int 1995; 47:618.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/52/36682/abstract/66\">",
"      Levine JW, Gota C, Fessler BJ, et al. Persistent cryoglobulinemic vasculitis following successful treatment of hepatitis C virus. J Rheumatol 2005; 32:1164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/52/36682/abstract/67\">",
"      Huart A, Bonnet F, Le Guenno G, et al. Prognostic factors of survival in patients with non-infectious mixed cryoglobulinaemia vasculitis: data from 242 cases included in the CryoVas survey. Ann Rheum Dis 2013; 72:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/52/36682/abstract/68\">",
"      Tarantino A, Moroni G, Banfi G, et al. Renal replacement therapy in cryoglobulinaemic nephritis. Nephrol Dial Transplant 1994; 9:1426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/52/36682/abstract/69\">",
"      Hiesse C, Bastuji-Garin S, Santelli G, et al. Recurrent essential mixed cryoglobulinemia in renal allografts. Report of two cases and review of the literature. Am J Nephrol 1989; 9:150.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3070 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-125.39.66.147-7DB0BEB7E6-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_52_36682=[""].join("\n");
var outline_f35_52_36682=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1906291\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GENERAL APPROACH TO THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17909481\">",
"      IMMUNOSUPPRESSIVE THERAPY FOR SEVERE MIXED CRYOGLOBULINEMIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17909544\">",
"      Patient selection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17909552\">",
"      Choice of immunosuppressive therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H571919\">",
"      - Preference for rituximab",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H571927\">",
"      - Rituximab regimen",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H543716\">",
"      - Preference for a rapid glucocorticoid taper",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1233191\">",
"      - Glucocorticoid regimen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Role of plasma exchange",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Plasma exchange prescription",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1230577\">",
"      Role of cyclophosphamide",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1576718960\">",
"      Antimicrobial prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17909507\">",
"      TREAT THE UNDERLYING DISORDER IN ALL PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Therapy for HCV infection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1233414\">",
"      - General approach to HCV therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1233455\">",
"      - Initiation of HCV therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1233463\">",
"      - Drugs and dosing in HCV therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H407972\">",
"      Evidence for efficacy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H546513\">",
"      - Duration of therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1233471\">",
"      - Monitoring of patients on antiviral therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Anti-HBV therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6575895\">",
"      Autoimmune disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6575986\">",
"      Lymphoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H571879\">",
"      Idiopathic disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H571871\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      END-STAGE RENAL DISEASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1906291\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/3070\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/3070|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?13/33/13853\" title=\"figure 1\">",
"      Cryos and LFTs after interferon",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/3070|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?26/32/27149\" title=\"table 1\">",
"      AASLD Rx chronic HBV recs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?15/56/16269\" title=\"table 2\">",
"      Chron HBV dosage adjustment",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"mobipreview.htm?29/57/30609?source=related_link\" title=\"calculator 1\">",
"      Calculator: Creatinine clearance estimate by Cockcroft-Gault equation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"mobipreview.htm?19/22/19809?source=related_link\" title=\"calculator 2\">",
"      Calculator: Creatinine clearance estimate by Cockcroft-Gault equation (SI units)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"mobipreview.htm?2/41/2706?source=related_link\" title=\"calculator 3\">",
"      Calculator: Ideal body weight (method of Devine) and dosing weight for adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/45/36570?source=related_link\">",
"      Assessment of kidney function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/15/34040?source=related_link\">",
"      Clinical manifestations and diagnosis of the mixed cryoglobulinemia syndrome (essential mixed cryoglobulinemia)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/30/11752?source=related_link\">",
"      Entecavir in the treatment of chronic hepatitis B virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/40/16008?source=related_link\">",
"      General principles of the use of cyclophosphamide in rheumatic and renal disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/25/26009?source=related_link\">",
"      Hepatitis B virus reactivation associated with immunosuppression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/47/29433?source=related_link\">",
"      Infection in the solid organ transplant recipient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/9/16538?source=related_link\">",
"      Management of the side effects of peginterferon and ribavirin being used for treatment of chronic hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/23/41337?source=related_link\">",
"      Mechanism of action and efficacy of peginterferon for the treatment of chronic hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/33/28184?source=related_link\">",
"      Mechanism of action and efficacy of ribavirin for the treatment of chronic hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/63/22522?source=related_link\">",
"      Overview of cryoglobulins and cryoglobulinemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/45/43735?source=related_link\">",
"      Overview of the management of chronic hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/51/24378?source=related_link\">",
"      Overview of the management of hepatitis B and case examples",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/38/41578?source=related_link\">",
"      Overview of the therapy and prognosis of systemic lupus erythematosus in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/12/12484?source=related_link\">",
"      Plasma exchange in the hyperviscosity syndrome due to immunoglobulins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/33/38420?source=related_link\">",
"      Prescription and technique of therapeutic plasma exchange",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/53/3928?source=related_link\">",
"      Renal disease associated with hepatitis C virus after renal transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/21/27990?source=related_link\">",
"      Response-guided therapy for chronic hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/24/36234?source=related_link\">",
"      Selecting antiretroviral regimens for the treatment naive HIV-infected patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/26/15785?source=related_link\">",
"      Studies of telaprevir and boceprevir in the treatment of chronic hepatitis C virus genotype 1",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/4/9289?source=related_link\">",
"      Treatment and prevention of Pneumocystis pneumonia in non-HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/14/2282?source=related_link\">",
"      Treatment of systemic and extraglandular manifestations of Sj&ouml;gren&rsquo;s syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/44/24258?source=related_link\">",
"      Treatment protocols for lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/47/24314?source=related_link\">",
"      Treatment regimens for chronic hepatitis C virus genotype 1",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/37/600?source=related_link\">",
"      Treatment regimens for chronic hepatitis C virus genotypes 2, 3, and 4",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_52_36683="Reduce difficult patient burdens";
var content_f35_52_36683=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F69677&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F69677&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Reducing the burden of difficult clinician-patient encounters",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Develop personal awareness",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Meditation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Balint groups",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Literature",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Journaling",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Co-teaching",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Psychotherapy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Advanced communication skills training with a personal awareness component",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Improve patient-centered interviewing skills",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Agenda-setting",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Eliciting patient's perspective",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Emotion-seeking skills",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Empathy skills (NURS)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Understand and appropriately respond to patent's personality characteristics",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Assess for patient complexity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Medical comorbidities",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Readiness to engage",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Social factors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Health system",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Resources for care",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_52_36683=[""].join("\n");
var outline_f35_52_36683=null;
var title_f35_52_36684="Xenografts";
var content_f35_52_36684=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F73182&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F73182&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Xenografts",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Source animal",
"      </td>",
"      <td class=\"subtitle1\">",
"       Tissue type",
"      </td>",
"      <td class=\"subtitle1\">",
"       Product",
"      </td>",
"      <td class=\"subtitle1\">",
"       Manufacturer",
"      </td>",
"      <td class=\"subtitle1\">",
"       Crosslinking",
"      </td>",
"      <td class=\"subtitle1\">",
"       Sterilization",
"      </td>",
"      <td class=\"subtitle1\">",
"       Host response",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"5\">",
"       Porcine",
"      </td>",
"      <td>",
"       Dermis",
"      </td>",
"      <td>",
"       DermMatrix&reg;",
"      </td>",
"      <td>",
"       Brennan Medical",
"      </td>",
"      <td>",
"       No",
"      </td>",
"      <td>",
"       Irradiation",
"      </td>",
"      <td>",
"       Replacement*",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Small intestine submucosa",
"      </td>",
"      <td>",
"       Surgisis&reg;",
"      </td>",
"      <td>",
"       Cook",
"      </td>",
"      <td>",
"       No",
"      </td>",
"      <td>",
"       Ethylene oxide",
"      </td>",
"      <td>",
"       Replacement",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Small intestine submucosa",
"      </td>",
"      <td>",
"       Fortagen&reg;",
"      </td>",
"      <td>",
"       Organogenesis",
"      </td>",
"      <td>",
"       EDC",
"      </td>",
"      <td>",
"       Not available",
"      </td>",
"      <td>",
"       Mixed&bull;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Dermis",
"      </td>",
"      <td>",
"       Pelvicol&reg;",
"      </td>",
"      <td>",
"       Bard",
"      </td>",
"      <td>",
"       HDI",
"      </td>",
"      <td>",
"       Irradiation&Delta;",
"      </td>",
"      <td>",
"       Encapsulation",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Dermis",
"      </td>",
"      <td>",
"       Pelvisoft&reg;",
"      </td>",
"      <td>",
"       Bard",
"      </td>",
"      <td>",
"       HDI",
"      </td>",
"      <td>",
"       Irradiation&Delta;",
"      </td>",
"      <td>",
"       Mixed",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"4\">",
"       Bovine",
"      </td>",
"      <td>",
"       Dermis",
"      </td>",
"      <td>",
"       Xenform&reg;",
"      </td>",
"      <td>",
"       Boston Scientific",
"      </td>",
"      <td>",
"       No",
"      </td>",
"      <td>",
"       Ethylene oxide",
"      </td>",
"      <td>",
"       Replacement*",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Pericardium",
"      </td>",
"      <td>",
"       Peri-Guard&reg;",
"      </td>",
"      <td>",
"       Synovis",
"      </td>",
"      <td>",
"       GLUT",
"      </td>",
"      <td>",
"       Propylene oxide",
"      </td>",
"      <td>",
"       Encapsulation*",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Pericardium",
"      </td>",
"      <td>",
"       Veritas&reg;",
"      </td>",
"      <td>",
"       Synovis",
"      </td>",
"      <td>",
"       No",
"      </td>",
"      <td>",
"       Irradiation&Delta;",
"      </td>",
"      <td>",
"       Replacement*",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Pericardium",
"      </td>",
"      <td>",
"       UroPatch&reg;",
"      </td>",
"      <td>",
"       YAMA",
"      </td>",
"      <td>",
"       GLUT",
"      </td>",
"      <td>",
"       Not available",
"      </td>",
"      <td>",
"       Encapsulation",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     EDC: 1-ethyl-3 (3-dimethylaminopropyl) carbodiimide hydrochloride; HDI: hexamethylene diisocyanate; GLUT: glutaraldehyde.",
"     <br>",
"      * Unpublished company communication.",
"      <br>",
"       &bull; Hypothesized based on chemical crosslinking and manufacturer's recommendation of preimplantation perforations, but no histologic studies available to confirm in vivo response.",
"       <br>",
"        &Delta; Gamma external beam radiation.",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_52_36684=[""].join("\n");
var outline_f35_52_36684=null;
var title_f35_52_36685="Long term cadaveric RT survival";
var content_f35_52_36685=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F56421&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F56421&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Recent improvement in short-term but not long-term cadaveric renal graft survival",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 449px; height: 235px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Data from the UCLA transplant registry on the trends in cadaveric renal graft survival between 1975 and 1990 at one-year (solid line) and over the long-term, expressed as the half-life of graft survival after the first year (dashed line). Late graft loss is primarily due to chronic rejection. Although there has been a progressive improvement in one-year graft survival, there has been little change in long-term survival with the half-life after the first year remaining between seven and eight years.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Gjertson, DW. In: Clinical Transplants 1991, Terasaki, P, Cecka, JM (Eds), UCLA Tissue Typing Laboratory, 1992, chap. 21.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_52_36685=[""].join("\n");
var outline_f35_52_36685=null;
var title_f35_52_36686="COPD Venn diagram";
var content_f35_52_36686=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F66708&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F66708&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 518px\">",
"   <div class=\"ttl\">",
"    Chronic obstructive pulmonary disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 498px; height: 342px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This nonproportional Venn diagram shows subsets of patients with chronic bronchitis, emphysema, and asthma (black circles). The subsets defined as COPD are shaded gray. Subset areas are not proportional to actual relative subset sizes. Asthma is, by definition, associated with reversible airflow obstruction; in variant asthma, special maneuvers may be necessary to make the obstruction evident. Patients with asthma whose airflow obstruction is completely reversible (subset 9) are not considered to have COPD. In many cases it is virtually impossible to differentiate patients with asthma whose airflow obstruction does not remit completely from persons with chronic bronchitis and emphysema who have partially reversible airflow obstruction with airway hyperreactivity. Thus, patients with unremitting asthma are classified as having COPD (subsets 6, 7 and 8). Chronic bronchitis and emphysema with airflow obstruction usually occur together (subset 5), and some patients may have asthma associated with these two disorders (subset 8). Individuals with asthma exposed to chronic irritation, as from cigarette smoke, may develop chronic productive cough, a feature of chronic bronchitis (subset 6). Such patients are often referred to in the United States as having asthmatic bronchitis or the asthmatic form of COPD. Persons with chronic bronchitis or emphysema without airflow obstruction (subsets 1, 2 and 11) are not classified as having COPD. In order to emphasize that cough and sputum are abnormal, individuals with these symptoms and normal lung function were classified as GOLD Stage 0, at risk, in the original GOLD classification [1]. This stage was deleted in the 2006 revision because of uncertainties about whether it is progressive [2]. Patients with airway obstruction due to diseases with known etiology or specific pathology, such as cystic fibrosis or obliterative bronchiolitis (subset 10), are not generally included in the definition of COPD.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     1. Data from: Global initiative for chronic obstructive lung disease (GOLD). Workshop report: Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease: Update 2005.",
"     <br>",
"      2. Data from: Global initiative for chronic obstructive lung disease (GOLD). Workshop report: Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease: Update 2006.",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_52_36686=[""].join("\n");
var outline_f35_52_36686=null;
var title_f35_52_36687="Pouch dilation after gastric banding";
var content_f35_52_36687=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F73273&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F73273&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 488px\">",
"   <div class=\"ttl\">",
"    Pouch dilation after gastric banding",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 468px; height: 351px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This esophagram demonstrates a pouch dilation. The treatment for this is to deflate the band and slowly inflate it again.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_52_36687=[""].join("\n");
var outline_f35_52_36687=null;
